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ABSTRACT 
 
 
The metabotropic glutamate receptor 5 (mGluR5) is a GPCR coupled to the 
heterotrimeric G protein Gαq/11 and activates signaling pathways important for excitatory 
synaptic transmission. Emerging studies reveal that Amyloid β (Aβ) acts as an 
extracellular scaffold for mGluR5. We have identified Ca2+/Calmodulin-dependent 
protein Kinase IIα (CaMKIIα) as an interacting protein of mGluR5. We hypothesize that 
CaMKIIα plays a role in mGluR5 signaling and Aβ produces differential effects on the 
regulation of mGluR5 by CaMKIIα.  We find that overexpression of CaMKIIα 
significantly impairs mGluR5-mediated ERK1/2 phosphorylation but does not effect 
inositol phosphate formation or Ca2+ release. We find that Αβ  increases the amount of 
co-immunoprecipitated CaMKIIα to mGluR5 and can activate mGluR5-mediated 
ERK1/2 phosphorylation via a PKC-dependent mechanism. mGluR5 and CaMKIIα are 
involved in learning and memory. Furthermore, Aβ and mGluR5 are implicated in 
Alzheimer’s disease. Thus, investigating how these proteins work together could provide 
insight for developing treatments for Alzheimer’s disease. 
KEYWORDS: G protein-coupled receptors, Metabotropic Glutamate 
Receptors, Ca2+/Calmodulin-dependent protein Kinase IIα, Receptor Signalling, 
Amyloid-β 
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CHAPTER 1 
INTRODUCTION 
1.1 G protein-coupled receptors 
G protein-coupled receptors (GPCRs) make up the largest family of 
transmembrane receptors that function to transduce extracellular signals into intracellular 
responses (Lagerstrom and Schioth, 2008).  GPCRs are composed of seven 
transmembrane domains and can be activated by a variety of stimuli including photons, 
odorants, hormones, amino acids, peptides and neurotransmitters (Hoon et al, 1999). 
Activation of GPCRs by agonist binding induces a conformational change in the receptor 
that allows GDP to be exchanged for GTP on the α subunit of the heterotrimeric GTP-
binding protein (G protein), subsequently leading to the disassociation of the α subunit 
from the receptor and the Gβγ subunit. These subunits activate or inhibit a variety of 
signaling pathways in order to modulate cellular functions (Neer, 1995). Factors affecting 
GPCR regulation have been studied intensively since they regulate many physiological 
functions and their dysregulation contributes to the development of many disease states. 
Furthermore, it is estimated that over 40% of all pharmaceutical drugs target GPCRs or 
their downstream effectors making them a prime target for the development of novel 
therapeutic agents (Zhang and Xie, 2012). 
GPCRs are classified into three main groups based on sequence homology. Class 
A includes the rhodopsin-like receptors, Class B includes the secretin/glucagon receptors, 
and Class C includes a unique member of GPCRs known as the metabotropic glutamate 
receptors (Lagerstrom and Schioth, 2008). The focus of this thesis will be on the 
metabotropic glutamate receptors.  
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1.2 Group I Metabotropic Glutamate Receptors 
Glutamate is the major excitatory neurotransmitter in the central nervous system. 
It exerts its effects by activating two distinct types of receptors: the ionotropic glutamate 
receptors and the metabotropic glutamate receptors (Figure 1.1). Activation of the 
ionotropic glutamate receptors such as the N-methyl-D-aspartate (NMDA) and Alpha-
amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA)/Kainate receptors 
mediates a fast and short lasting cellular response by opening cation channels. In order to 
produce a slow and long lasting cellular response, glutamate activates the metabotropic 
glutamate receptors (Conn and Pin, 1997; Nakanishi, 1992). There are eight metabotropic 
glutamate receptors divided into three subgroups based on the signaling pathways they 
activate, sequence homology and pharmacological characteristics. The Group I 
metabotropic glutamate receptors (mGluR1 and mGluR5) are excitatory and are coupled 
to Gαq. The Group II (mGluR2 and mGluR3) and Group III metabotropic glutamate 
receptors (mGluRs4, mGluR6, mGluR7 and mGluR8) are similar in that they are 
involved in presynaptic inhibition by coupling to Gαi. However, these receptors differ in 
their agonist selectivity (Nakanishi, 1994; Conn and Pin, 1997). The focus of this thesis 
will be on the Group I mGluRs. 
 
1.2.1 Structure and functional domains 
The general structure of Group I mGluRs consists of a long amino (N)-terminal 
extracellular domain tail, seven transmembrane domains separated by short intracellular 
and extracellular loops, and an intracellular carboxyl (C)-terminal domain that varies in 
length between splice variants (Pinn and Duvoisin, 1995). Interestingly, mGluRs share 
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very little sequence homology with prototypic GPCRs and thus have unique structural 
differences. Unlike prototypic GPCRs where ligand binding involves pocket formation 
by the seven transmembrane domains, glutamate binding to mGluRs involves the N-
terminal domain (Chun et al., 2012). Group I mGluRs have a long N-terminal domain 
consisting of 600 amino acids. Structural studies have indicated that the glutamate 
binding site is located in this region and forms a ‘clam shell’ upon glutamate binding. 
This type of ligand binding is known as the venus fly trap model (Kunishima et al., 
2000). Besides functioning as ligand binding domains, the N-termini of Group I mGluRs 
form disulphide bridges which allows for the formation of dimers (Beqollari and 
Kammermeier, 2010). 
In contrast to prototypic GPCRs, where G protein coupling selectivity is mediated 
by the third intracellular loop, mGluRs have a highly conserved third intracellular loop, 
which does not determine G protein coupling selectivity. Instead, G protein coupling 
selectivity of mGluRs is mediated by the second intracellular loop where differences exist 
between different subtypes of mGluRs (Gomeza et al., 1996). In addition, the second 
intracellular loop is an important site for interaction  with regulatory proteins such as G 
protein-coupled receptor kinase 2 (GRK2), proline-rich tyrosine kinase 2 (pyk2) and 
calcineurin inhibitor (CAIN) (Dhami et al., 2002, Nicodemo et al., 2010; Ferreira et al., 
2009). 
Diversity in the Group I mGluRs occurs as a result of alternative splicing 
mechanisms within the C-terminal tail. mGluR1 consists of four splice variants 
(mGluR1a, b, c and d) and mGluR5 consist of two splice variants (a and b). mGluR1a has 
a long C-terminal tail consisting of 313 amino acids.  In contrast, the mGluR1b/c/d splice 
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variants have short C-terminus tails (20 residues for mGluR1b, 11 for mGluR1c and 26 
for mGluR1d) (Conn and Pin, 1997). The differences in length contribute to the 
differences in affinity for agonists: mGluR1a has a higher affinity for agonist than the 
shorter mGluR1 splice variants (Flor et al., 1996).  Moreover, splice variants display 
differential distribution in the central nervous system (Ferraguti et al., 1998). Both 
mGluR5a and mGluR5b splice variants have long C-terminal tails. The C-terminal tail of 
mGluR5a is 344 amino acids in length and mGluR5b contains an additional 32 amino 
acids (Joly et al, 1995) (Figure 1.1). Because of the large C-terminal tail of Group I 
mGluRs this region is important for interacting with many regulatory proteins. The C-
terminus of Group I mGluRs encodes for binding motifs for PP1γ1, SIAH-1a, Homer and 
PDZ domain containing proteins (Enz, 2012). In addition, the C-terminal tail is important 
for G protein coupling (Francesconi and Duvoisin, 1998). 
Pharmacologically, Group I mGluRs are selectively activated by the Group I 
mGluR agonist (S)-3,5-Dihydroxyphenylglycine (DHPG). The most potent agonist of the 
Group I mGluRs is quisqualic acid, although it can also activate the AMPA receptors. 
Currently there are no agonists that differentiate between mGluR1 and mGluR5, however 
the synthetic agonist CHPG is more selective for mGluR5 than mGluR1 (Doherty et al., 
1997). There are also antagonists which are selective for the two receptor subtypes: 2-
Methyl-6-(phenylethynyl) pyridine (MPEP) is non-competitive inhibitor of mGluR5 and 
LY367385 competitively inhibits mGluR1 (Gasparini et al., 1999; Clark et al., 1997).  
 
1.2.2 Distribution 
              Group I mGluRs display differential distribution patterns throughout the central 
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Figure 1.1  Schematic illustration  of membrane topology of rat mGluR5. The 
mGluR5b splice variant contains an insert of 32 additional amino acids after L875. 
Several binding domains for interacting proteins are labeled as well as potential PKC and 
CaMKII phosphorylation sites. Residues involved in Gαq/11 coupling are highlighted in 
yellow. (Taken from Mao et al., 2008) 
 
 
 
6 
nervous system which may contribute to the functional differences observed between 
mGluR1 and mGluR5 (Ferraguti and Shigemoto 2006). mGluR1 is highly expressed in 
the Purkinje cells of the cerebellum, CA3 pyramidal cells of the hippocampus, olfactory 
bulb, thalamus and substantia nigra. In contrast, mGluR5 is expressed in only 10% of the 
Golgi cells of the cerebellum, but is found to have a higher expression in the cortex, 
striatum, olfactory bulb and the CA1 and CA3 pyramidal cells of the hippocampus 
(Ferraguti and Shigemoto, 2006). The expression of Group I mGluRs in the hippocampus 
plays a role in long-term potentiation (LTP) and spatial learning (Neyman and Manahan-
Vaughan, 2008; Balschun et al., 1999). Meanwhile, the predominant expression of 
mGluR1 in the cerebellum is reported to play a role in long- term depression (LTD) 
induction and motor learning (Aiba et al., 1994).  
More complexity occurs as a result of differential distribution of mGluR1 splice 
variants. A prime example is the predominant expression of mGluR1a in the cerebral 
Purjinke cells and mGluR1b in the hippocampal pyramidal cells (Ferraguti et al., 1998). 
In contrast, only slight differences occur in the expression of the two mGluR5 isoforms 
although it has been shown that mGluR5a predominates in the young rat brain while 
mGluR5b is predominately found in the adult rat brain (Joly et al., 1995; Romano et al., 
1996). In addition, mGluR5 expression is also observed in other cell-types of the brain 
such as astrocytes and microglia (Schools and Kimelberg, 1999; Biber et al., 1999). 
Besides the central nervous system, Group I mGluRs have been shown to be present in 
the rat spinal cord, heart cells, hepatocytes, osteoblasts and human melanocytes (Dhami 
and Ferguson, 2006).   
At the subcellular level, the Group I mGluRs are predominately located on the 
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perisynaptic region of the post synaptic membrane where they can modulate ion channels 
to regulate neuronal excitability (Lujan et al., 1996). Interestingly, mGluR5 is also 
expressed on the intracellular membranes of the endoplasmic reticulum and nucleus, 
where it plays a role in regulating gene expression and activates signaling cascades 
distinict from cell surface counterparts (Kumar et al., 2012; Jong et al., 2009). 
 
1.2.3 Group I metabotropic glutamate receptor signaling 
As previously mentioned, Group I mGluRs are coupled to Gαq/11. Upon agonist 
stimulation, Group I mGluRs change conformation allowing the exchange of GDP to 
GTP on the Gαq/11 protein. The activation of the Gαq/11 protein results in the activation of 
phospholipaseCβ (PLCβ) which hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2) 
on the plasma membrane producing the second messengers diacylglycerol (DAG) and 
inositol 1,4,5-trisphosphate (IP3). IP3 interacts with the IP3 receptor on the endoplasmic 
reticulum resulting in the release of Ca2+ from intracellular stores. The increase in both 
Ca2+ and DAG activates protein kinase C (PKC) which in turn can activate other 
downstream signaling pathways (Pinn and Duvoisin, 1997).  Although Group I mGluRs 
are predominately coupled to Gαq/11, they have also been shown to couple to other G 
proteins, such as Gαs and Gαi/o in a variety of cell lines (Franscesconi and Duvoisin 1998; 
Ribeiro et al., 2010a). Activation of Gαs stimulates adenylyl cyclase to produce cAMP, 
an important second messenger. Conversely, activation of Gαi/o negatively regulates 
adenylyl cyclase and inhibits cAMP formation. 
  Activation of PKC can lead to the activation of phospholipase D, phospholipase 
A2, mitogen activated protein kinase (MAPK) as well as the modulation of a variety of 
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ion-channels (Dhami and Ferguson, 2006).  mGluR1-mediated PKC activation has been 
shown to phosphorylate the NMDA receptor leading to increased NMDA receptor 
channel conductance, and therefore enhanced synaptic excitability (Skeberdis et al., 
2001). In addition, PKC is believed to be involved in the two distinct types of Ca2+ 
responses. mGluR5-mediated Ca2+ signaling is unique from that of mGluR1 as mGluR5 
activation results in high frequency Ca2+ oscillations, whereas activation of mGluR1 
shows low frequency Ca2+ oscillations (Kawabata et al., 1998, Dale et al. 2001). The 
proposed mechanism involves the repetitive translocation of PKC between the cytoplasm 
and the plasma membrane in response to repetitive G protein coupling. The oscillation 
frequency is controlled by a single amino acid residue in the G protein coupling domain 
that differs between mGluR1 and mGluR5 (Dale et al., 2001). The activation of MAP 
kinases through Group I mGluRs involves a variety of mechanisms and will be discussed 
in detail below.  
 
1.2.4 Activation of Mitogen Activated Kinases 
 
Protein phosphorylation is a common post-transcriptional modification that 
functions to either activate or deactivate an enzyme and is widely seen in signaling 
cascades. The mitogen-activated protein (MAP) kinases are a family of serine/threonine 
kinases involved in the transduction of externally derived signals. This family includes 
the extracellular signal-regulated kinases ERK1 and ERK2, also known as p42/p44 MAP 
kinases. ERK1/2 can be activated by a variety of cell surface receptors and therefore acts 
as convergence point for integration of signals (Roskoski, 2012). Initially, ERK1/2 
activation was studied in mitogenic signaling downstream of receptor tyrosine kinases. In 
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this signaling cascade, activation of Ras leads to the activation of the protein kinase c-raf 
which in turn activates the mitogen-activated protein kinase kinases (MEK1 and MEK2). 
MEK1/2 are dual function kinases that in turn carry out the phosphorylation and 
activation of ERK1/2 (Roskoski, 2012). Activated ERK1/2 have a variety of cellular and 
nuclear substrates that they act upon to regulate cell adhesion, migration, differentiation, 
proliferation, and transcription (Roskoski, 2012). Interestingly, this signaling pathway is 
upregulated in a variety of cancers (Pearson et al., 2001).  
ERK1/2 phosphorylation can also be induced through activation of GPCRs 
including the Group I mGluRs through a number of mechanisms depending on cell type 
(Ferraguti et al., 1999; Choe and Wang, 2001; Karim et al., 2001). Group I mGluR-
mediated ERK1/2 phosphorylation is observed in Chinese hamster ovary cell lines 
(Thandi et al., 2002). In this cell line mGluR5-mediated ERK1/2 activation is Ca2+-
independent, although other studies using striatal neurons have reported that Ca2+ release 
from intracellular stores via the activation of PLCβ contributes partially to ERK1/2 
phosphorylation (Mao et al., 2005a). In striatal neurons mGluR5-mediated ERK1/2 
activation is largely due to interaction with Homer proteins (Mao et al., 2005a). 
Homer1b/c proteins directly interact with mGluR5 to couple the receptor to ERK1/2 
phosphorylation, since the disruption of the mGluR5-Homer1b/c interaction by TAT 
interference peptides inhibits ERK1/2 phosphorylation (Mao et al., 2005a). In rat striatal 
neurons mGluR5 mediated ERK1/2 phosphorylation appears to involve protein 
phosphatase 2A (PP2A) (Mao et al., 2005b). mGluR5 associates with PP2A and 
activation of mGluR5 inhibits this interaction and decreases PP2A activity. 
Consequently, the decrease in PP2A activity contributes to mGluR5-mediated ERK1/2 
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phosphorylation (Mao et al., 2005b). Our lab has found that pyk2 facilitates mGluR1-
dependent ERK1/2 phosphorylation in mouse cortical neurons (Nicodemo et al., 2010) 
In cortical astrocytes, mGluR5-mediated ERK2 activation is independent of 
PLCβ1 however and requires the transactivation of the EGF receptor, a receptor tyrosine 
kinase (Peavy et al., 2001). Interestingly, it appears that transactivation of receptor 
tyrosine kinases is a common mechanism by which GPCRs activate the ERK1/2 pathway 
as this mechanism is described for a variety of GPCRs such as the thrombin, angiotensin 
II, bradykinin, endothelin, and purinergic receptors (Daub et al., 1997; Soltoff, 1998; 
Adomeit et al., 1999; Della Rocca et al., 1999; Seo et al., 2000).  
Another important pathway for ERK1/2 activation involves β-arrestins. β-
arrestins are well known for their role in the desensitization and internalization of GPCRs 
(Ferguson 2001). However, they have also been reported to function as signal transducers 
by forming signaling complexes (Ferguson, 2001; Luttrell and Lefkowitz, 2002). Emery 
et al., (2010) found that sustained activation of ERK1/2 phosphorylation through 
mGluR1 is dependent on β-arrestin1. This signaling pathway is distinct from the G 
protein-mediated transient ERK1/2 phosphorylation and is shown to be neuroprotective 
(Emery et al., 2010). β-Arrestin-mediated ERK1/2 signaling has also been reported for 
other GPCRs including the angiotensin II type 1a receptor (Luttrell et al., 2001), D3 
dopamine receptor (Beom et al., 2004), β2-adrenergic receptor (Luttrell et al., 1999; 
Shenoy et al., 2006) and the µ opioid receptor (Macey et al., 2006). 
 
1.2.5 Regulation by interacting proteins 
Protein interactions with GPCRs represent a large source for novel drug targets. 
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Group I mGluRs interact with a number of regulatory proteins that are important for 
receptor trafficking, protein scaffolding and coupling to distinct signaling cascades (Enz, 
2012). Work done in our laboratory has characterized the interaction between GRK2, 
CAIN and Pyk2 with the second intracellular loop domain of Group I mGluRs (Dhami et 
al., 2002, Ferreira et al., 2009, Nicodemo et al., 2010). GRK2 interacts with the second 
intracellular loop, as well as the C-terminal tail of Group I mGluRs. This interaction 
functions to attenuate Group I mGluR-mediated signaling and contributes to 
phosphorylation-independent internalization of Group I mGluRs in striatal neurons 
(Dhami et al, 2002, 2004, 2005; Ribeiro et al., 2009). Similarly, CAIN interacts with the 
second intracellular loop and C-terminus tail and attenuates mGluR1-mediated signaling 
(Ferreira et al., 2009). As previously mentioned, the second intracellular loop is important 
for G protein coupling. It appears that the interaction between second intracellular loop 
interacting proteins disrupts coupling to Gαq/11 thus attenuating the signaling response.  
The long C-terminus tail of Group I mGluRs also harbours binding sites for many 
interacting proteins. The most studied are the Homer proteins, which are a family of 
multifaceted scaffolding proteins (Thomas 2002). Homer proteins bind to the proline rich 
region of the C-termius tail of Group I mGluRs and are proposed to physically link both 
mGluR1 and mGluR5 to the IP3 receptor thereby modulating Ca2+ release (Tu et al., 
1998). In addition, the interaction between mGluR5 and Homer3 has been shown to 
prevent constitutive activity of the receptor (Ango et al., 2001). Other proteins interact 
with the C-terminal tail to modulate receptor cell surface expression and trafficking.  
Calmodulin (CaM) interacts with mGluR5 and is reported to play a role mGluR5 
trafficking (Lee et al., 2008). Specifically, CaM overexpression increases cell surface 
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expression of mGluR5 while the knockdown of CaM decreases cell surface expression. 
CaM also competes with PKC for binding to the C-tail of mGluR5 and thus regulates 
PKC-mediated trafficking of mGluR5 (Lee et al., 2008). 
 
1.2.6 Physiological roles of Group I mGluRs 
 
Group I mGluRs have been extensively studied in experimental animals leading to 
the conclusion that they are involved in many aspects of brain function. In the brain, 
activation of Group I mGluRs plays a complex role that can be both neuroprotective and 
neurotoxic (Nicoletti et al., 1999; Caraci et al., 2012). Group I mGluRs have been 
implicated in the two forms of synaptic plasticity: LTP and LTD, indicating that are 
involved in the underlying mechanisms for learning and memory (Riedel and Reyman 
1996, Ayala et al., 2009; Neyman and Vaughan, 2008). LTP involves a mechanism in 
which persistent synaptic activity leads to a pronounced increase in synaptic strength. In 
contrast, in LTD an absence of synaptic activity leads to a pronounced decrease in 
synaptic strength (Anwyl, 1999).   
LTP is thought to occur in two phases: early phase LTP and late phase LTP. Early 
phase LTP is mediated by the activation of NMDA receptors which results in increased 
intracellular Ca2+ and subsequent activation of CaMKII (Lisman et al., 2002). CaMKII is 
responsible for strengthening of the synapse by increasing the number of AMPA 
receptors on the synaptic membrane (Lynch, 2004). Importantly, the insertion of AMPA 
receptors at the synapse occurs in a protein synthesis independent manner. This is 
achieved by the trafficking of existing nonsynaptic AMPA receptors to the synaptic 
membrane (Malinow, 2003). In contrast, late phase LTP depends on protein synthesis and 
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activation of mGluRs (Neyman and Vaughan, 2008). There is now a considerable amount 
of evidence that shows that certain forms of LTP are dependent on Group I mGluRs (Lu 
et al., 1997; Jia et a., 1998; Neyman and Vaughan, 2008). The perisynaptic localization of 
Group I mGluRs at excitatory synapses puts these receptors at an ideal location for 
regulating synaptic strength. One mechanism involves the mGluR5-mediated 
enhancement of NMDA receptor conductance (Attuci et al., 2001). In line with this, 
studies on mGluR5 knockout mice have revealed that NMDA-dependent LTP in the CA1 
region of the hippocampus is reduced and that these mice exhibit impaired learning (Lu et 
al., 1997; Jia et a., 1998).  
Besides their role in normal brain functions, Group I mGluRs have also been 
implicated in a variety of neurological disorders. Perhaps the most studied is the role of 
mGluR5 in the pathogenesis of Fragile-X syndrome. Fragile-X syndrome is the leading 
genetic cause of autism in which the gene encoding for Fragile-X mental retardation 
protein (FMRP) is silenced (Pieretti et al., 1991). FMRP is an RNA binding protein that 
selectively binds to 4% of mammalian mRNAs and represses their translation (Ashley et 
al., 1993). mGluR5 plays an important role in Fragile-X since both inhibition mGluR5 
signaling and knockdown of mGluR5 improves Fragile-X phenotypes in FMRP knockout 
mice (Bear et al., 2004; Dölen and Bear, 2008). Additionally, mGluR-dependent LTD is 
exaggerated in the hippocampus of FMRP knockout mice which could impair synaptic 
plasticity and lead to memory deficits (Luscher and Huber, 2010) 
Because of their involvement in LTP and LTD,  it is no surprise that Group I 
mGluRs play a role in neurodegenerative diseases that affect learning and memory such 
as Huntington’s and Alzheimer’s diseases (Ribeiro et al., 2010). Huntington’s disease is 
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an autosomal-dominant neurodegenerative disorder that affects muscle coordination, 
cognition and mental behavior (Ribeiro et al., 2011). Our lab has demonstrated that 
Group I mGluR signaling is altered in a knock-in mouse model of Huntington’s disease 
(Ribeiro et al., 2010b; Ribeiro et al., 2014). Specifically, Group I mGluR mediated IP3 
formation is decreased and Ca2+ release is increased compared to wild type control 
(Ribeiro et al., 2010b). Moreover, the mGluR5 antagonist MPEP is reported to prolong 
survival in a mouse model of Huntington’s disease (Schiefer et al., 2004).  
Several studies have implicated Group I mGluRs in Alzheimer’s disease. 
Alzheimer’s disease is a progressive neurodegenerative disease characterized by 
cognitive impairment, memory loss and behavioral changes (Tsai et al, 2005). 
Alzheimer’s disease has a distinct pathology consisting of Amyloid β (Aβ) plaques and 
tangles of hyperphosphorylated tau (Holzman et al., 2011; Nelson et al., 2009; Hardy et 
al., 2002). Aβ can exert its effects by blocking LTP thereby reducing synaptic plasticity. 
Wang et al., (2004) found that the Aβ-mediated inhibition of LTP can be prevented by 
the mGluR5 antagonist MPEP. Recently it has been shown that genetic deletion of 
mGluR5 reverses spatial memory deficits in the APPswe/PS1E9 mouse model of 
Alzheimer’s disease (Hamilton et al., 2014). Furthermore, genetic deletion of mGluR5 in 
this mouse model results in reduced Aβ oligomer formation compared to the 
APPswe/PS1E9 mice expressing mGluR5 (Hamilton et al., 2014). Taken together, these 
observations suggest that Group I mGluRs are important regulators of normal brain 
function and dysregulation of these receptors can be a factor in disease progression.  
 
1.3 Amyloid β  
 
Aβ is formed from the sequential cleavage of the amyloid precursor protein (APP) 
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by β- and γ-secretases (Vardy et al., 2005). APP is a transmembrane protein that can be 
processed by two alternate pathways. In the non-amyloidogenic pathway, α-secretase 
cleaves APP within the Aβ region thus preventing the formation of the Aβ peptide.  In 
the amyloidogenic pathway, APP is initially cleaved by β-secretase resulting in the 
release of the N-terminal fragment, sAPPβ. The remaining C-terminal of APP is 
membrane bound and is cleaved by γ-secretase to produce Aβ peptide and amyloid 
intracellular domain (Figure 1.2) (Vardy et al., 2005; Chow et al., 2009). Once cleaved, 
Aβ peptide can form a variety of structures including monomers, oligomers and fibrils 
(Zhang et al., 2011). Cleavage by γ-secretase results in a number of Aβ peptide isoforms 
that vary in length between 39 and 43 amino acids. Aβ40 and Aβ42 are the most common 
Aβ  species. However, Aβ42 peptides assemble more readily into oligomeric forms and 
are a major component of amyloid plaques (Selkoe 2006; Kellett and Hooper, 2009). 
Furthermore, Aβ42 oligomers correlate better with neurotoxicity than any other form of 
Aβ (Lacor et al., 2007;  Butterfield 2002) 
Aβ oligomers can exert their toxic affects by targeting synapses and contributing 
to synaptic dysfunction and synaptic loss (Lacor et al., 2007, Shankar et al., 2007). In 
addition, several studies have indicated that Aβ-mediated toxicity involves inhibition of 
LTP (Walsh et al., 2002). Aβ can suppress both early phase and late phase LTP which 
can explain the learning and memory deficits associated with Alzheimer’s disease (Chen 
et al., 2000, Zhang et al., 2009; Li et al., 2009). The exact molecular mechanisms 
underlying Aβ-mediated toxicity are largely unknown. It is proposed that Aβ oligomers  
may  exert  their  neurotoxic  effects  by  interacting  with  several  cell  surface  receptors 
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Figure 1.2. Schematic illustration of the β- and γ-site cleavage events required for 
Aβ  formation. The amyloid precursor protein (APP) is a 100 kDa transmembrane 
protein that is initially cleaved at the beta site by the enzyme BACE.  This releases the 
extracellular APP fragment β-APP leaving the C-terminal APP C99 fragment in the 
membrane.  Cleavage at the beta site can be followed by a second cleavage within the 
membrane domain of APP by the γ-secretase complex to produce beta amyloid (Aβ).  
This “gamma-cleavage” determines the relative amount of the more toxic 42 amino acid 
form of Aβ produced. 
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(Dinamarca et al., 2012). Several studies have shown that Aβ can affect the function of 
NMDA receptors. Aβ binds to the NMDA receptor, contributes to NMDA receptor 
endocytosis and depresses NMDA receptor-evoked currents. (Snyder et al., 2005; 
Shankar et al., 2007). Aβ can also bind to the α7-nicotinic acetylcholine receptor (α7-
nAChR) with high affinity (Wang et al., 2000). The same group discovered that the α7-
nAChR can mediate Aβ peptide-induced tau protein phosphorylation (Wang et al., 2003). 
Aβ42 oligomers have been shown to bind with high affinity to the cellular prion protein 
(PrPC) and reduce LTP in hippocampal slices of wildtype mice but not PrPC-null mice, 
suggesting that PrPC mediates Aβ42 oligomer toxicity (Lauren et al., 2009). PrPC is a 
glycosylphosphatidylinositol-anchored membrane protein that is highly expressed within 
the central nervous system (Linden et al., 2007). Its pathogenic form, the abnormally 
folded scrapie prion protein PrPSc, is well known for its role in neurodegenerative 
disorders known as transmissible spongiform encephalopathies (Linden et al., 2007).  
Normal physiological roles of PrPC include neuroprotection to oxidative stress, cell 
adhesion and neurite growth (Linden et al., 2007).  
Recent studies have shown that Aβ42 oligomers may produce their toxic effects 
through mGluR5 (Renner et al., 2010). Aβ42 oligomers induce clustering of mGluR5 
resulting in limited lateral diffusion of the receptors and elevated Ca2+ levels that cause 
synaptic deterioration (Renner et al., 2010). Additionally, mGluR5 has been shown to be 
a co-receptor for the Aβ oligomer-PrPC complex (Um et al., 2013). Aβ oligomers can 
increase intracellular Ca2+ in neurons in a manner that is dependent on both mGluR5 and 
PrPC.  
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1.4 Ca2+/ Calmodulin-dependent protein kinase II 
Regulation of Ca2+ signaling is a vital component in the maintenance of cellular 
homeostasis. In the brain, Ca2+ signaling regulates many aspects of neuronal excitability 
by interacting with a variety of Ca2+ sensitive proteins (Zundorf and Reiser, 2011).  
Ca2+/CaM-dependent protein kinase II (CaMKII) is a serine/threonine kinase that is 
sensitive to Ca2+ signaling since it is activated by Ca2+/CaM binding when intracellular 
Ca2+ is increased. CaMKII comprises a family of 28 similar isoforms derived from four 
genes (α, β, γ, and δ). The expression of the γ and δ isorforms is ubiquitous whereas the 
α and β isoforms are restricted to neuronal tissue (Lisman et al., 2002). CaMKIIα and 
CaMKIIβ are highly abundant in the brain where they are estimated to make up 1-2% of 
the total protein (Erondu and Kennedy, 1985). Specifically, CaMKIIα/β is expressed in 
the cortex, striatum, cerebellum, hypothalamus, olfactory bulb and its highest expression 
is observed in the hippocampus (Erondu and Kennedy, 1985). At the subcellular level, 
CaMKIIα/β can be found in the cytoplasm as well as a protein dense region of the post-
synaptic membrane known as the post synaptic density (PSD) (Hanson and Schulman, 
1992). This thesis will focus on the CaMKIIα isoform. 
 
1.4.1 Structure and activation of CaMKII 
Each isoform of CaMKII consists of an autoinhibitory domain, a catalytic 
domain, a self-association domain and a variable segment. The self-association domain at 
the C-terminus allows for the assembly of a holoenzyme comprised of 12 subunits. The 
resulting structure resembles that of a hub and spoke in which the catalytic domains are 
arranged in a ring around a central scaffold formed by the self-association domains 
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(Lisman et al., 2002; Chao et al., 2011). Under basal conditions, the autoinhibitory 
domain binds to the catalytic domain, preventing any kinase activity. An increase in 
intracellular Ca2+ favours Ca2+/CaM to bind to the autoinhibitory domain relieving the 
inhibition to the catalytic domain. This allows for the exposure of the Thr 286 site on the 
autoinhibitory domain (Thr 287 on CaMKIIβ), which can be phosphorylated by adjacent 
subunits of CaMKII in a process known as autophosphorylation. Once this site is 
phosphorylated the autoinhibitory domain can no longer inhibit the catalytic domain and 
the catalytic domain can remain active even after Ca2+/CaM levels fall. This contributes 
to the persistent or autonomous activity of the kinase (Hanson and Schulman, 1992). Two 
molecules of Ca2+/CaM are required to initiate the activation of the CaMKII holoenzyme. 
One binds to one subunit and activates it while the other Ca2+/CaM molecule binds to an 
adjacent subunit in order to expose the Thr 286/287 site which gets phosphorylated by the 
activated subunit. In contrast, propagation of activating all 12 subunits requires binding 
of only one Ca2+/CaM molecule to a subunit adjacent to the one that is already 
phosphorylated (Figure 1.3) (Lisman et al., 2002). 
 
1.4.2 Role of CaMKII 
CaMKII can phosphorylate a broad range of substrates and regulate a variety of 
cellular functions. In the heart, CaMKIIδ has been shown to be in involved in 
cardiomyocyte hypertrophy by regulating the expression of hypertrophic markers (Zhang 
and Brown, 2004). In the brain, CaMKII has been shown to be an important player in 
synaptic plasticity. The Threonine residue 286 on CaMKIIα in particular, has been shown 
to contribute to the induction of LTP (Lisman et al., 2002; Lee et al., 2009). It was found 
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Figure 1.3 Representative diagram of CaMKII structure and activation. Each 
CaMKII subunit is composed of a self-association domain, a catalytic domain and an 
autoinhibitory domain. Twelve subunits of CaMKII join together at the self-association 
domain to form a holoenzyme. Under basal conditions, the autoinhibitory domain binds 
to the catalytic domain to inhibit its activity. Upon Ca2+/CaM binding the catalytic 
domain becomes active and can phosphorylate an adjacent CaMKII subunit. 
Phosphorylation keeps the autoinhibitory domain from inhibiting the catalytic domain 
even after Ca2+/ CaM fall resulting in autonomous activity of the enzyme. (Taken from 
Lisman et  al., 2002) 
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that prevention of CaMKIIα activation by mutation of this residue results in impaired 
LTP induction and mice exhibiting this mutation show profound memory impairment 
(Giese et al., 1998; Lucchesi et al., 2011). Furthermore, mice exhibiting enhanced 
learning have increased activation of CaMKII (Lee and Silvia, 2009) 
 
1.4.3 Regulation of ionotropic glutamate receptors. 
CaMKII plays an important role in LTP by interacting with the ionotropic 
glutamate receptors. Once CaMKII is activated by increased intracellular Ca2+, it can 
translocate from the cytoplasm to the PSD (Shen and Meyer, 1999). Here, CaMKII can 
bind to a variety of different proteins and receptors. The binding to the NMDA receptor 
has been key to elucidating the role of CaMKII in LTP induction. It is well established 
that stimulation of NMDA receptors in cultured neurons produces an increase in Ca2+ 
influx which activates CaMKII. Activated CaMKIIa can then translocate to the PSD 
where it binds to the NR2B subunit of the NMDA receptor (Strack et al., 1997; Leonard 
et al., 1999). The formation of the NMDA-CaMKII complex has been shown to play an 
important role in LTP since transgenic mice overexpressing a mutant form of NR2B 
which interferes with CaMKII binding have a 50% reduction in LTP and show learning 
impairments (Barria and Malinow, 2005; Zhou et al., 2007). Importantly, the binding of 
CaMKII to the NMDA receptor keeps the kinase in an active state (Bayer et al., 2001). 
LTP induction and maintenance is also dependent on AMPA receptor activity. 
One mechanism involves the phosphorylation of AMPA receptors at a specific residue 
within the GluR1 subunit by CaMKII (Lee et al., 2000). The translocation of CaMKII to 
the PSD puts the kinase at an ideal location to phosphorylate the Ser 831 residue on the 
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GluR1 subunit of AMPA receptors leading to an increase in conductance of these 
channels and enhanced LTP (Barria et al., 1997; Poncer et al., 2002).  Another 
mechanism involves the increase in AMPA receptors in the synapse. AMPA receptor 
trafficking to the synapse is positively regulated by the stargazin-PSD95 complex 
(Schnell et al., 2002; Bats et al., 2007). It is hypothesized that CaMKII potentiates this by 
phosphorylating stargazin which allows stargazin to bind to PSD95 thereby increasing the 
number of AMPA receptors at the cell surface (Lisman et al., 2012). These mechanisms 
work together to enhance LTP. 
 
1.4.4 Regulation of G protein-coupled receptors 
Emerging studies reveal that CAMKIIα can also regulate several GPCRs. 
CaMKIIα has been shown to regulate behavioral responses to cocaine by regulating the 
Dopamine 3 (D3) receptor, a GPCR coupled to Gαi (Liu et al., 2008).  CaMKIIα binds to 
the long third intracellular loop of the D3 receptor and activation of CaMKIIα by 
Ca2+/CaM, as well as Thr 286 autophosphorylation enhances the interaction to the D3 
receptor. CaMKIIα phosphorylates the D3 receptor and contributes to receptor 
desensitization, thereby relieving the inhibition of cAMP accumulation induced by D3 
receptor agonists (Liu et al., 2008). CaMKIIα-dependent desensitization has also been 
reported for the D1/D2 heterodimer (So et al., 2008) and the Histamine H1 receptor 
(Hishinuma and Ogura, 2000). 
Another Gαi coupled GPCR, the M4 muscharinic acetylcholine receptor has been 
shown to be regulated by CaMKIIα (Guo et al., 2010). CaMKIIα binds to the second 
intracellular loop of the M4 receptor and potentiates its signaling. Interestingly, this 
interaction is enhanced by CaMKIIIα activation and autophosphorylation similar to that 
which occurs at the D3 receptor. Experiments using interference peptides designed to 
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block this interaction block the M4 receptor-mediated decrease in cAMP accumulation 
(Guo et al., 2010). Consequently, because motor activity in the brain is coordinated by 
M4 receptors, the CaMKIIα regulation of M4 receptor contributes to the integration of 
signals required for motor control (Guo et al., 2010).  
CaMKIIα is well studied in context of the ionotropic glutamate receptors. 
However, very little is known about the effects of CaMKIIα on metabotropic glutamate 
receptors. Of all eight mGluRs, CaMKIIα has only been reported to regulate mGluR1 
(Mundell et al., 2002; Jin et al., 2013a). CaMKIIα appears to play a role in mGluR1 
internalization: inhibition of CaMKIIα blocks the glutamate-stimulated association of 
GRK2 with mGluR1a suggesting CaMKIIα plays a role in inhibiting mGluR1 
internalization (Mundell et al., 2002).  Recently, CaMKIIα has been shown to play a 
direct role in the regulation of mGluR1 by physically interacting with the C-terminus tail 
of mGluR1 (Jin et al., 2013a). Similar to that of the D3 dopamine and M4 muscarinic 
receptor, activation of CaMKIIα by Ca2+/CaM binding as well as autophosphorylation 
potentiates CaMKIIα binding to mGluR1. In rat striatal neurons, stimulation with DHPG 
increases the amount of CaMKIIα co-immunoprecipitated with mGluR1a showing that 
this occurs in physiologically relevant tissue. Functionally, CaMKIIα phosphorylates 
mGluR1 at Thr 871 on the C-terminus tail and desensitizes mGluR1 mediated IP3 
production in rat striatal neurons (Jin et al., 2013a). These studies suggest that CaMKIIα 
can be an important regulator of GPCR activity including mGluR1. 
 
1.5 Preliminary data and rationale 
In collaboration with Dr. Stephane Angers, we have identified CaMKIIα as a 
novel second intracellular loop (IL2) interacting protein of Group I mGluRs. A 
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membrane permeant Tat-IL2-FLAG peptide was used to screen for novel IL2 interacting 
proteins. Mouse cortical neurons were treated with the Tat-IL2-FLAG peptide and the 
Tat-IL2-FLAG peptide was subsequently immunoprecipitated with FLAG agarose beads. 
Immunoprecipitates were trypsinized and analyzed by Maldi-TOF Mass Spectroscopy. 
mGluR1-IL2 interacting proteins identified in the screen included CaMKII isoforms α, β, 
γ, δ. 
Work done previously in our laboratory by Stephanie Kulhawy as part of her 
M.Sc. thesis has confirmed the interaction between CaMKIIα and Group I mGluRs in 
HEK 293 cells. When FLAG-mGluR1/5 was immunoprecipitated, co-
immunoprecipitation of GFP-CaMKIIα occurred with both mGluR1a and mGluR5a and 
this interaction was independent of agonist stimulation with quisqualate. Additionally, 
CaMKIIα was shown to interact with mGluR5 in mouse hippocampal tissue indicating 
that this interaction takes place in physiologically relevant tissue. Furthermore, using a 
GST-pull down assay, it was established that the second intracellular loop of mGluR1 is 
sufficient for this interaction to occur.  
When looking at the effects of CaMKIIα on mGluR1a signaling, it was found that 
CaMKIIα overexpression had no significant effect on mGluR1a-mediated ERK1/2 
phosphorylation or IP3 formation. However the role of CaMKIIα on mGluR5-mediated 
signaling remains unknown. Additionally, it was found that CaMKIIα significantly 
enhances agonist-mediated mGluR5 internalization but not mGluR1 internalization 
suggesting that CaMKIIα has more of a pronounced effect on mGluR5. Therefore this 
thesis will focus on the role of CaMKIIα on mGluR5 activity. 
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1.6 Goals and Significance of Research 
Interacting proteins play a vital part in GPCR regulation.  As previously 
addressed, CaMKII has been shown to be an important regulator of GPCRs including 
mGluR1. Furthermore, it is well established that the second intracellular loop of Group I 
mGluRs is an important region for receptor regulation by interacting proteins. 
Preliminary data provide evidence for a role for CaMKIIα in mGluR5 internalization, 
however whether CaMKIIa plays a role in mGluR5 signaling is unknown. In this study 
we hypothesize that CaMKIIα plays a role in regulating mGluR5 mediated signaling and 
that Aβ oligomer interactions with mGluR5 may alter CaMKIIα/mGluR5 interactions. 
We hypothesized that Aβ oligomers will produce differential effects on the regulation of 
mGluR5 by CaMKII. 
 As previously mentioned, mGluR5 is involved in a variety of signaling pathways 
that can be both neuroprotective and neurotoxic. However, factors that differentiate 
between these outcomes are poorly understood. Furthermore, alterations in the regulation 
of mGluR5 may lead to the progression of several neurodegenerative diseases. Therefore, 
by elucidating the roles of its interacting proteins, such as CaMKIIα, on mGluR5 
regulation, we may begin to better understand the mechanisms by which mGluR5 is 
regulated, as well as identify novel therapeutic targets for the treatment of 
neurodegenerative diseases related to mGluR5. 
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CHAPTER 2 
 
MATERIALS AND METHODS 
 
2.1 Materials 
 
Human embryonic kidney (HEK293) cells were obtained from American Type 
Culture Collection (Manassas, VA, USA). Fetal Bovine Serum (FBS), minimum essential 
medium (MEM), Dulbecco’s Modified Eagle Medium (DMEM), 0.25% trypsin, and 
rabbit anti-GFP antibody were all purchased from Invitrogen Corporation (Burlington, 
ON, Canada). Goat anti-rabbit IgG (H+L)-HRP conjugate secondary antibody, ECL 
western blotting detection reagents, Dowex 1-X8 (formate form) resin 200-400 mesh and 
Bradford reagent for protein assays were all obtained from Bio-Rad (Mississauga, ON, 
Canada). Sheep anti-mouse IgG secondary antibody and Protein G Sepharose 4 Fast Flow 
were from GE Healthcare (Mississauga, ON, Canada). Phospho-p44/42 MAP kinase 
antibody and p44/42 MAP kinase antibody were purchased from Cell Signaling 
Technology (Mississauga, ON, Canada). Anti-FLAG antibody and rabbit anti-FLAG M2 
Agarose were purchased from Sigma (St. Louis, MO, USA). Anti–mGluR5 rabbit IgG 
was purchased from Millipore (Billerica, MA, USA). Quisqualate and KN-93 were 
purchased from TOCRIS (Minneapolis, MN, USA). Myo-[3H] Inositol was purchased 
from Perkin Elmer (Waltham, MA, USA). Fura-2 AM and Zenon antibody labelling 
reagents were purchased from Molecular Probes (Billerica, MA, USA). Aβ42 peptide was 
purchased from American Peptide (Vista, CA, USA). Bisindolymaleimide I (Bis-1) 
hydrochloride was purchased from Calbiochem (San Diego CA, USA). The GFP-
CAMKIIα cDNA was a gift from Dr. Paul De Koninck (University Laval).  
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2.2 Cell culture and transfection 
 
HEK 293 cells were maintained in MEM supplemented with 10% (v/v) fetal 
bovine serum at 37°C in a humidified atmosphere containing 5% CO2. Cells were plated 
on 100 mm dishes and transfected using a modified Ca2+ phosphate method (Ferguson 
and Caron, 2004) with the amount of cDNA indicated in the Figure Legends. Briefly, 
cDNAs were diluted in 450 µL of sterile distilled water and 50 µL of 2.5M CaCl2 was 
added to the mix. Next, 500 µL of 2X HEPES-balanced salt solution (0.28 M NaCl, 
0.05M HEPES, 1.5 mM Na2HPO4, pH 7.10) was slowly dripped over the cDNA/CaCl2 
solution. The solution was mixed and immediately applied to cells grown to 75-85% 
confluency drop by drop. Cells were washed twice with PBS 16-18 hours after 
transfection and allowed to recover in MEM for 6 hours before being reseeded for 
experimentation. Experiments were performed the following day except otherwise 
indicated. 
 
2.3 Co-immunoprecipitation 
 
HEK 293 cells were transiently transfected with various cDNA constructs as 
described in the Figure Legends. One day after transfection, cells were starved for 1 hour 
in HBSS (1.2 mM KH2PO4, 5 mM NaHCO3, 20 mM HEPES, 11 mM Glucose, 116 mM 
NaCl, 4.7 mM KCl, 1.2 mM MgSO4, 2.5mM CaCl2, pH 7.4) and subsequently stimulated 
as indicated in the Figure Legends. Cells were then lysed with ice-cold lysis buffer. (50 
mM Tris, pH 8.0, 150 mM NaCl, and 0.1% Triton X-100) and insoluble material was 
pelleted. FLAG-mGluR5 was immunoprecipitated from transfected HEK 293 cell lysates 
using FLAG M2-Agarose prepared as a 50:50 slurry with PBS. 200 µg of protein was 
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rotated with 50 µl of the slurry for 1 hour at 4°C. The beads were washed 3 times with 
PBS and eluted with 100 µl of SDS loading buffer containing β-mercaptoethanol. The 
eluted proteins were subjected to SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
and immunoprecipitated and co-immunoprecipitated proteins were detected by Western 
Blot. 
 
2.4 GST pull down 
 
 GST-mGluR1a-IL2 and mutants were cloned into a pGEX4T1 vector and 
transformed into E.coli recombinant bacteria. E. coli bacteria were grown at 37°C with 
shaking until OD600 was 0.6-1.0. Cultures were then induced with 1 mM isopropyl 1-thio-
β-D-galactopyranoside for 3 hours at 23°C. Cells were pelleted and lysed in lysis buffer 
(500 mM NaCl, 0.5% NP-40, 50 mM Tris pH7.6, 5 mM EDTA, 5 mM EGTA) 
containing protease inhibitors (2 mM AEBSF, 50 mg/ml aprotinin, 20 mg/ml leupeptin) 
and sonicated (3 times for 10 seconds) at 4°C. Insoluble material was pelleted at 15000 g 
for 15 minutes at 4°C. 50 µl of Glutathione-Sepharose bead slurry was incubated 
overnight with 1 ml of solubilized protein to purify GST-fusion constructs. Glutathione-
Sepharose beads were then washed 3 times in PBS and 500 µg of HEK 293 cell lystate 
overexpressing GFP-CAMKIIα was added to the GST-fusion peptide bound to matrix 
and rotated for 1 hour at 4°C. Glutathione-Sepharose beads were then washed 6 times in 
PBS and eluted with 3X SDS loading buffer containing β-mercaptoethanol. Samples were 
subjected to SDS-PAGE and membranes were immunoblotted with GFP to determine if 
GFP-CAMKIIα was pulled down with the GST-mGluR1a-IL2 peptides. 
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2.5 ERK1/2 phosphorylation 
 
Twenty-four hours after transfection, cells were reseeded into 6-well dishes. The 
following day, cells were starved in DMEM overnight. On the day of experiment, cells 
were starved for an additional hour in HBSS. Cells were then stimulated at 37°C with 
either 50 µM Quisqualate or 100 nM Aβ42 oligomers as indicated in the Figure Legends. 
For experiments using the PKC inhibitor, 1 µM Bis-1 or DMSO (vehicle) was added 30 
minutes prior to stimulating cells. Cells were subsequently lysed in lysis buffer (25 mM 
HEPES, 300 mM NaCl, 1.5 mM MgCl2, 200 µM EDTA, 1% Triton-X) containing 
protease and phosphatase inhibitors ( 1 mM AEBSF, 25 mg/ml aprotinin, 10 mg/ml 
leupeptin, 10 mM NaF, 100 µM Na3VO4) rocking at 4°C. Lysates were collected and 
centrifuged at 15000 RPM for 15 minutes at 4°C. Protein concentration was determined 
using a Bradford protein assay. The lysates were mixed with SDS loading buffer 
containing β-mercaptoethanol prior to gel loading. ERK1/2 phosphorylation was 
determined by immunoblotting for phospho-ERK1/2 and Total-ERK1/2 and the ratio was 
normalized to basal levels. 
 
2.6 Inositol phosphate formation 
Forty-eight hours after transfection, inositol lipids were radiolabelled by 
incubating HEK293 cells overnight with 1 µCi/ml [3H]myo-inositol in DMEM. 
Unincorporated [3H]myo-inositol was removed by washing the cells 3X with warm 
HBSS. HEK 293 cells were then incubated for 1 hour in warm HBSS at 37°C and then 
for an additional 10 minutes in HBSS containing 10 mM LiCl. Subsequently, cells were 
treated with increasing concentrations of quisqualate (0-30 µM) for 30 minutes at 37°C. 
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The reaction was terminated by placing the cells on ice and adding 500 µl of 0.8 M 
perchloric acid and then neutralized with 400 µl of 0.72 M KOH and 0.6 M KHCO3. 
Total [3H]myo-inositol incorporated into the cells was determined by counting the 
radioactivity present in 50 µl of cell lysates. Total inositol phosphate was purified from 
the cell lysates by anion exchange chromatography using Dowex 1-X8 (formate form) 
200-400 mesh anion exchange resin. [3H]myo-inositol phosphate formation was 
determined by liquid scintillation using a Beckman LS 6500 scintillation counter. 
 
2.7 Calcium Imaging 
 HEK 293 cells were washed 2X in KRH buffer (125 mM NaCl, 5 mM KCl, 2 
mM CaCl2, 2.6 mM MgSO4, 5 mM HEPES, pH 7.2). mGluR5 was labelled with rabbit 
anti-FLAG-conjugated Zenon Alexa Fluor 555 antibody for 20 minutes. Intracellular 
Ca2+ was then labeled with 5 µM fura-2 acetoxymethyl ester (AM) in KRH buffer for 30 
minutes and washed off prior to loading onto PTI DeltaRam microscope. Cells 
expressing both FLAG-mGluR5 and GFP-CaMKII or GFP empty vector were selected to 
be imaged. Fluorescence intensity was examined by illuminating the cells with 340 and 
380 nm and the intensity values at each excitation were recorded. After obtaining a one 
minute baseline, cells were stimulated with 30 µM Quisqualate for 5 minutes. 
Concentration of Ca2+ was obtained by using the formula [Ca2+] = Kd * [R-Rmin]/ 
[Rmax-R] * Fmax/Fmin, where R is the Fura-2 340/380 ratio, Kd =.761 µM, 
Rmin=0.196, Rmax=6.907, and Fmax/Fmin=9.558, as determined by calibration 
experiments. Area under the curve was determined using GraphPad software. 
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2.8 Immunofluorescence confocal microscopy 
 
Confocal microscopy was performed using a Zeiss LSM-510 laser scanning 
microscope equipped with a Zeiss 63X 1.4 numerical aperture oil immersion lens. Live 
cell imaging was performed on HEK293 cells in 35mm glass-bottomed plates. mGluR5 
was labelled with rabbit anti-FLAG conjugated Zenon Alexa Fluor 647 antibody and 
PrPC was labeled with mouse anti-PrPC conjugated Zenon Alexa Fluor 555 IgG2B 
antibody. Visualization of labelled proteins with GFP-CaMKIIα was performed by triple 
excitation (488/543/647 nm), and emissions were collected using these filter sets: band 
pass from 505-530 (GFP), long pass at 560 (Alexa Fluor 555) and 660 (Alexa Fluor 647). 
For internalization experiments, FLAG-mGluR5 was labelled with rabbit anti-FLAG-
conjugated Zenon Alexa Fluor 555 antibody. Visualization of antibody-labelled receptor 
with GFP-CaMKIIα was performed by dual excitation (488/543 nm) and emission band 
pass from 505-530 (GFP) and long pass at 560 (Alexa Fluor 555) filter sets. Receptor was 
stimulated with the addition of 30 µM Quisqualate (final concentration) for 20 minutes.  
 
2.9 Immunoblotting 
 
 Nitrocellulose membranes were blocked for 1 hour with 10% milk in Tris-
buffered Saline with Tween 20 (TBS-T) (150mM NaCl, 10 mM Tris HCl pH 7.0, and 
0.05% Tween 20) and subsequently incubated overnight with primary antibody (1:1000) 
in TBS-T containing 3% milk. Membranes were washed 3X in TBS-T and then incubated 
with secondary horseradish peroxidase conjugated goat anti-rabbit IgG (1:5000) or sheep 
anti-mouse IgG (1:5000) in TBS-T containing 3% milk for 1 hour. Membranes were then 
rinsed 3X with TBS-T and incubated with enhanced chemiluminescence Western blotting 
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detection reagents and visualized using a Chemidoc Imaging System.  
 
2.10 Aβ42  oligomer formation 
 
 Aβ42 peptides stored at -80°C were allowed to equilibrate to room temperature 
prior to dilution to 1 mM with 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP). HFIP was 
evaporated in a vacuum centrifuge in order to form Aβ42 peptide films and films were 
then stored at -80°C.  Prior to use, Aβ42 peptide films were diluted in 
dimethylsulphoxide (DMSO) to 1 mM and sonicated for 10 minutes in a Branson 
sonicator. Aβ42 peptides were then subsequently diluted to 100 µM in ice-cold F-12 cell 
culture media (phenol free red), vortexed immediately for 30 seconds, and incubated at 
4°C for 24 hours in order to form Aβ42 oligomers. 
 
2.11 Statistical Analysis 
 
 The means ± S.E.M. are shown for values obtained for the number of independent 
experiments indicated in the Figure Legends. Immunoblots were quantified using Image 
Lab software. GraphPad Prism software was used to analyze data for statistical 
significance as well as to analyze and fit dose-response curves. Statistical significance 
was determined by either an unpaired two-tailed t-test or by one-way ANOVA followed 
by Tukey’s or Dunnett’s  multiple comparison’s test.  
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CHAPTER 3 
 
RESULTS 
 
3.1 Characterization of the interaction between CAMKIIα and mGluR5 
 
 CaMKIIα was previously shown to interact with mGluR1 (Jin et al., 2013a). We 
also previously identified CaMKIIα as an mGluR1/5 interacting protein following 
immunoprecipitation of the 2nd intracellular loop domain (IL2) of mGLuR1a/5a to 
identify mGluR1a/5a interacting proteins by proteomic analysis (Angers and Ferguson, 
unpublished observations). Consistent with this experiment, we found that GFP-
CaMKIIα could be co-immunoprecipitated with the full-length FLAG-tagged mGluR5a 
in transfected HEK 293 cells in an agonist-independent manner (Fig. 3.1A).   
Ca2+/CaM has been demonstrated to bind to the regulatory domain of CaMKIIα to 
activate the kinase. This activation can regulate the affinity of CaMKIIα for its targets 
such as the NMDA receptor (Shen and Meyer, 1999) and previous studies showed that 
activation of CaMKIIα by Ca2+/CaM increases its interaction to GPCRs such as the D3 
receptor, the M4 muscarinic receptor and mGluR1a (Liu et al., 2008; Guo et al., 2010; Jin 
et al., 2013a). Therefore, we examined whether inhibition of CaMKIIα activity can 
decrease the association between CaMKIIα and FLAG-mGluR5a as determined by co-
immunoprecipitation. KN-93 is a CaMKII inhibitor which prevents activation by binding 
to the Ca2+/CaM binding site on the kinase (Sumi et al., 1991). Agonist stimulation of 
mGluR5a did not affect the amount of GFP-CaMKIIα co-immunoprecipitated with 
FLAG-mGluR5a and KN-93 treatment did not affect the amount of GFP-CaMKIIα co-
immunoprecipitated with FLAG-mGluR5a indicating that this interaction was agonist- 
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Figure 3.1. CaMKIIα co-immunoprecipitates with mGluR5 independent of agonist 
stimulation and CaMKIIα activity. (A) Representative immunoblot of GFP-CaMKIIα 
co-immunoprecipitated with FLAG-mGluR5a in HEK 293 cells transiently transfected 
with 2 µg of FLAG-mGluR5 and 0.5 µg of GFP-CaMKIIα as labelled. Cells were 
stimulated with 30 µM quisqualate for the indicated time points. (B) Representative 
immunoblot of GFP-CaMKIIα co-immunoprecipitated with FLAG-mGluR5a in HEK 
293 cells transiently transfected with 2 µg of FLAG-mGluR5 and 0.5 µg of GFP-
CaMKIIα as labelled. Cells were treated with  5 µM of the CaMKIIα inhibitor KN-93 for 
1 hour. (C) Effect of KN-93 treatment was quantified by densitometry and had no 
significant effect on the amount of GFP-CaMKIIα co-immunoprecipitated with FLAG-
mGluR5. Data are representative of the mean ± S.E.M of five independent experiments. 
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and CaMKIIa-activity independent (Fig. 3.1 B and C).  GFP-CaMKIIα is localized in the 
cytosplasm when expressed alone in HEK293 cells and when co-expressed with FLAG-
mGluR5 (Figure 3.2 A and B). Stimulation of mGluR5 with quisqualate does not alter the 
distribution of GFP-CaMKIIα (Fig. 3.2C). 
 We identified CaMKIIα as a novel mGluR1a/5a second intracellular loop (IL2) 
interacting protein, therefore we assessed whether CaMKIIα could be co-precipitated 
with a series of purified GST fusions protein corresponding to the IL2 of mGluR5a (Fig. 
3.3A).  We found that the CaMKIIα could be co-precipitated with the wild-type IL2 of 
mGluR5a (Fig. 3.3B). Alanine scanning mutagenesis of the mGluR5a IL2 did not result 
in mutations that completely prevented CaMKIIα association with the intracellular loop 
domain (Fig. 3.3B and C).  However, we found that GFP-CaMKIIα displays reduced 
binding to GST-MUT2 compared to the wild type IL2 (Figure 3.3B and C). Interestingly, 
this region of mGluR1 was also important for binding to GRK2.  More specifically, the 
binding site of GRK2 was localized to K691 and K692 (Dhami et al., 2005). We then 
tested the co-immunoprecipitation of GFP-CAMKIIα to the full length mGluR1b receptor 
and the K691A and K692A mutants within the MUT2 region. We found that these 
mutations were not sufficient to block binding to GFP-CAMKIIα (Figure 3.3D and E). 
Therefore, it appears that CaMKIIα is not localized to a specific region within the IL2 of 
mGluR1. 
 
3.2 Effect of CAMKIIα on mGluR5-mediated signaling in HEK 293 cells 
 It has been well established that activation of Group I mGluRs turns on Gα/q11 
which results in the activation of PLC, IP3 formation and Ca2+ release from intracellular 
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Figure 3.2. Localization of CaMKIIα and mGluR5a using confocal microscopy. (A) 
Representative confocal microscopy image showing the subcellular localization of GFP- 
CaMKIIα (green) when expressed alone HEK 293 cells.  (B) Representative confocal 
image demonstrating the localization of FLAG-mGluR5 (red) labelled with Zenon Alexa 
Fluor 555-conjugated rabbit anti-FLAG antibody and GFP-CaMKIIα (green). (C) 
Representative confocal image demonstrating the internalization of FLAG-mGluR5 (red) 
labelled with Zenon Alexa Fluor 555-conjugated rabbit anti-FLAG antibody  and GFP-
CAMKIIα (green) during 20 minutes of stimulation with quisqualate. HEK 293 cells 
were transfected with 2 µg of receptor and 0.5 µg of GFP-CaMKIIα plasmid cDNA. Data 
are representative of over 20 cells. 
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Figure 3.3. CaMKIIα interaction with GST-mGluR1-IL2 mutants. 
(A) Schematic representation of the second intracellular loop (IL2) alanine scanning 
mutant GST peptides. (B) GST and GST-fusion proteins as labeled were purified from E. 
coli recombinant bacteria using Glutathione-Sepharose. Matrix bound GST-fusion 
peptides were incubated for 1 hour with lysate from HEK 293 cells overexpressing GFP-
CaMKIIα and samples were analyzed by Western blotting. Shown is a representative 
immunoblot of GST-fusion peptides and associated GFP-CaMKIIα. (C) Quantification of 
the amount of recovered GFP-CaMKIIα was normalized to each GST-fusion protein and 
expressed as a percentage of GFP-CaMKIIα binding to GST-IL2.  GFP-CaMKIIα 
showed reduced binding to GST-MUT2. Data shown are means ± S.E.M of four 
independent experiments. (D) Representative immunoblot of immunoprecipitated 
mGluR1b and mGluR1b mutants (K691A and K692A) with co-immunoprecipitated 
GFP-CaMKIIα. (E) Quantification of co-immunoprecipitated GFP-CaMKIIα analyzed 
using Image Lab software. Data shown are means ± S.E.M of three independent 
experiments. 
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stores (Dhami and Ferguson, 2006). CaMKIIα was previously found to desensitize 
mGluR1-mediated IP formation in striatal neurons (Jin et al., 2013a). Therefore, we 
examined whether GFP-CaMKIIα overexpression leads to an alteration of FLAG-
mGluR5-mediated IP formation. Here we employed a mutant FLAG-mGluR5 cDNA 
construct that has a single amino acid mutation (A154V) in the glutamate binding region. 
This residue is analogous to Ala 168 in mGluR1 which when mutated to valine results in 
low basal IP formation, but can respond to agonist stimulation (Esseltine et al., 2012). 
Without GFP-CaMKIIα overexpression, we were able to produce a dose-response curve 
for quisqualate-induced IP formation with FLAG-mGluR5aA154V. However, we found 
that overexpression of GFP-CaMKIIα did not alter mGluR5a-mediated IP formation (Fig. 
3.4A). Additionally, we tested whether overexpression of GFP-CaMKIIα had an effect on 
mGluR5-mediated Ca2+ release. It has been previously established that activation of 
mGluR5 induces Ca2+ oscillations (Kawabata et al., 1999; Dale et al., 2001). We 
observed Ca2+ oscillations in HEK 293 cells following activation of mGluR5a with 
quisqualate (Fig. 3.5A and B). We found that GFP-CaMKIIα overexpression did not 
affect the total amount of mGluR5-mediated Ca2+ release as quantified by area under the 
curve (Fig. 3.5C). GFP-CaMKIIα overexpression also did not affect the frequency of 
oscillations compared to control cells transfected with GFP despite the trend that there 
appears to be a higher frequency of oscillations with GFP- CaMKIIα overexpression (Fig. 
3.5D). 
 In addition to IP3 formation and Ca2+ release, mGluR5 activation leads to the 
activation of ERK1/2. Therefore, we tested whether GFP-CaMKIIα overexpression might 
alter mGluR5-mediated ERK1/2 phosphorylation in HEK 293 cells. We found that 
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Figure 3.4. CaMKIIα does not have a significant effect on mGluR5-mediated inositol 
phosphate (IP) formation. (A) Dose response curves for mGluR5-mediated IP 
formation in response to treatment with increasing concentrations of quisqualate (0-30 
µM) for 30 minutes in cells transfected with 2 µg of plasmid cDNA expressing FLAG-
mGluR5A154V along with either 0.5 µg of plasmid cDNA expressing GFP-CAMKIIα or 
0.5 µg of empty pEGFP vector. (B) Representative immunoblot showing equivalent  
FLAG-mGluR5 expression in GFP and  GFP-CaMKIIα transfected cells. The data 
represent the mean ± S.E.M of five independent experiments. 
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Figure 3.5. CaMKIIα has no affect on mGluR5-mediated Ca2+ release. 
Representative traces of the oscillatory Ca2+ response induced by 30 µM quisqualate in 
HEK 293 cells transiently transfected with 2 µg of pcDNA3.1 encoding FLAG-mGluR5a 
and 0.5 µg of cDNA encoding GFP (A) or GFP-CAMKIIα (B). Cells were imaged to 
establish a baseline recording for 1 minute and then stimulated with 30 µM quisqualate 
for 5 minutes. (C) Quantification of the Ca2+ concentration represented as area under the 
curve (AUC). (D) Quantification of the frequency of oscillations as number of 
oscillations in a 5 minute period. Data is presented as mean ± S.E.M for 26-29 cells from 
four independent experiments. 
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overexpression of GFP-CaMKIIα resulted in a significant decrease in FLAG-mGluR5a 
mediated ERK1/2 phosphorylation and  following 10 minutes of stimulation with 50 µM 
quisqualate this effect was statistically significant. (Fig. 3.6 A and B). Thus, CaMKIIα 
overexpression selectively attenuated mGluR5a-mediated ERK1/2 phosphorylation 
without affecting IP formation or Ca2+ release. 
 
3.3 Effect of Aβ42  on mGluR5 activity 
 
Several studies have shown that Aβ42 oligomers correlate better with cognitive 
impairment and synaptic loss than any other Aβ species (Selkoe, 2006). Current evidence 
suggests that the excitatory postsynaptic membrane represents a main target of Aβ 
toxicity (Lacor et al., 2007). Aβ oligomers can interact with a variety of cells surface 
receptors to modulate their function such as α7-nicotinergic acetylcholine receptor, 
NMDA and AMPA receptors, Eph2B and mGluR5 (Snyder et al., 2005; Hsieh et al., 
2006, Cisse et al., 2011; Um et al., 2013). We tested the affect of Aβ42 oligomers on the 
interaction between CaMKIIα and mGluR5a. HEK 293 cells overexpressing FLAG-
mGluR5a and GFP-CaMKIIα were treated with 200 nM Aβ42 oligomers for 0, 2, 5, 15, 
and 30 minutes and GFP-CaMKIIα binding to FLAG-mGluR5a was assessed by co-
immunoprecipitation. We found that treatment with 200 nM Aβ42 oligomers increases 
the amount of GFP-CaMKIIα co-immunoprecipitated with mGluR5a over time and 
produced a significant increase in CaMKII co-immunoprecipitated with mGluR5a 
following 15 minutes of stimulation (Fig. 3.7A and B). Thus, Aβ42 oligomers can alter 
the association between mGluR5 and CaMKIIα. Aβ42 oligomers have been shown to 
induce   mGluR5a-mediated   Ca2+   release  (Um et al., 2013).  However   whether   Aβ42 
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Figure 3.6.  CAMKIIα overexpression significantly decreases mGluR5-mediated 
ERK1/2 phosphorylation. HEK 293 cells were transiently transfected with 2 µg of 
pcDNA3.1 encoding FLAG-mGluR5a and 0.5 µg cDNA expressing GFP-CaMKIIα or 
pEGFP vector as labeled. Cells were stimulated with 50 µM quisqualate for the indicated 
time points. (A) Representative immunoblot of FLAG-mGluR5a, GFP-CaMKIIα, 
Phospho-ERK1/2 and Total-ERK1/2. (B) Quantification of  phosphorylated ERK1/2 
compared to total ERK1/2 as fold-increase over basal. GFP-CAMKIIα significantly 
decreased ERK1/2 phosphorylation during 10 minutes of quisqualate stimulation as 
analyzed by Student’s two-tailed t-test. *p<0.05. Data are mean ± S.E.M of five 
independent experiments. 
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Figure 3.7.  Αβ42  oligomers increase the amount of co-immunoprecipitated 
CAMKIIα to mGluR5a. HEK 293 cells were transiently transfected with 2 µg of 
pcDNA3.1 encoding FLAG-mGluR5a and 0.5 µg cDNA encoding GFP-CaMKIIα as 
labelled. Cells were treated with 200 nM Αβ42 oligomers for the indicated time points. 
(A) Shown is a representative immunoblot for immunoprecipitated FLAG-mGluR5a, co-
immunoprecipitated GFP-CaMKIIα, and GFP-CaMKIIα inputs. (B) Quantification of co-
immunoprecipitated GFP-CaMKIIα was done using Image Lab software. Treatment with 
Αβ42 oligomers for 15 minutes significantly increases the amount of co-
immunoprecipitated GFP-CaMKIIα compared to untreated control. *p< 0.05. Data is 
presented as mean ± S.E.M fold increase over untreated control of five independent 
experiments. 
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oligomers can activate mGluR5a-mediated ERK1/2 phosphorylation was unknown. 
Therefore, we tested whether Aβ42 oligomers (100 nM) could activate ERK1/2 
phosphorylation in HEK 293 cells overexpressing FLAG-mGluR5a. We found that 
treatment with Aβ42 oligomers for 5 minutes results in over 2-fold increase in ERK1/2 
phosphorylation and over 4-fold increase with 10 minutes of stimulation in cells 
overexpressing FLAG-mGluR5a (Fig. 3.8A and B). Cells that were not transfected with 
the receptor did respond to Aβ42 oligomer treatment (Fig. 3.8A and B). In addition, it 
was found that overexpression of GFP-CaMKIIα did not impair the ERK1/2 
phosphorylation induced by Aβ42 oligomers when compared to control cells expressing 
GFP (Fig.3.8A and B) suggesting that  Aβ42 oligomers can differentially regulate 
mGluR5 a-mediated ERK1/2 signaling. 
ERK1/2 activation following Group I mGluR activation can occur through a 
variety of mechanisms as previously discussed in Chapter 1.2.4. Therefore, we tested 
whether Aβ42-mediated ERK1/2 activation occurred via a PKC-dependent mechanism. 
HEK293 cells were incubated in HBSS with DMSO (vehicle) or the PKC inhibitor 
bisindolymaleimide I (Bis-1)  prior to stimulation with 30 µΜ quisqualate or 100 nM 
Aβ42 oligomers for 5 minutes and ERK1/2 phosphorylation was assessed. We found that 
PKC inhibition significantly reduced FLAG-mGluR5a mediated ERK1/2 
phosphorylation induced by both quisqualate and Aβ42  oligomers (Figure 3.9A and B). 
Thus Aβ42-mediated ERK1/2 activation was PKC-dependent.  
Αβ42 oligomers were shown to interact with PrPC with high affinity and this 
complex could interact with mGluR5 to mediate signaling (Um et al., 2013). Using 
confocal microscopy we determined the effect of PrPC and mGluR5a co-expression on 
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Figure 3.8. Aβ42 oligomers can activate mGluR5a-mediated ERK1/2 
phosphorylation. HEK 293 cells were transiently transfected with 2 µg of pcDNA3.1 
encoding FLAG-mGluR5 and 0.5 µg cDNA and pEGFP encoding CaMKIIα or pEGFP as 
labelled. Cells were stimulated with 100 nM Αβ42 oligomers for the indicated time 
points. (A) Representative immunoblot of FLAG-mGluR5, Phospho-ERK1/2 and Total-
ERK1/2. (B) Quantification of  phosphorylated ERK1/2 compared to total ERK1/2 as 
fold over basal. CaMKIIα has no significant effect on the mGluR5a-mediated ERK1/2 
phosphorylation induced by 100 nM Αβ42 oligomers p>0.05. Data are mean ± S.E.M of 
four independent experiments. 
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Figure 3.9. Αβ42 mediated ERK1/2 activation is PKC-dependent. HEK 293 cells 
were transiently transfected with 2 µg of pcDNA3.1 encoding FLAG-mGluR5 and 
stimulated with 30 µM quisqualate or 100 nM Αβ42 oligomers in the absence or presence 
of 1 µM bisindolymaleimide I (Bis-1). (A) Representative immunoblot of  FLAG-
mGluR5, phospho-ERK1/2 and total-ERK1/2. (B) Quantification of  phosphorylated 
ERK1/2 compared to total ERK1/2 as fold over basal. PKC inhibition with Bis-1 
significantly reduces mGluR5a-mediated ERK1/2 phosphorylation induced by 
quisqualate and Αβ42 oligomers *p<0.05. The data represent the mean ± S.E.M of seven 
independent experiments 
 
 
 
48 
 
CaMKIIα distribution. We found that cells co-expressing these cell surface proteins 
showed a higher percentage of redistribution of GFP-CAMKIIα into punctuate clusters 
(Fig.3.10A) compared to cells expressing PrPC and mGluR5 individually. This effect did 
not occur in cells transfected with empty GFP vector. (Figure 3.10B).  This suggests that 
CaMKIIα distribution may be affected by the mGluR5-PrPC interactions. 
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Figure 3.10. PrPC overexpression results in redistribution of subcellular GFP- 
CaMKIIα. HEK 293 cells were transiently transfected with 2 µg of pcDNA3.1 encoding 
FLAG-mGluR5a, 2 µg of pcDNA3.1 encoding PrPC  and 0.5 µg of GFP-CaMKIIα or 
empty pEGFP vector (control). Representative confocal microscopy images showing cell 
surface FLAG-mGluR5a (red) labelled with Zenon Alexa Fluor 647-conjugated rabbit 
FLAG antibody, PrPC (blue) labelled with Zenon Alexa Fluor 555-conjugated mouse 
PrPC antibody  and GFP-CaMKIIα (A) or empty pEGFP vector (B). Data are 
representative of over 70 cells for each transfection. 
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CHAPTER 4 
 
DISCUSSION 
 
The excitatory neurotransmitter glutamate mediates many physiological processes 
in the central nervous system through ionotropic and metabotropic glutamate receptors 
(Ozawa et al., 1998; Nakanishi, 1992). The Group I mGluRs play a key role in neuronal 
development, learning and synaptic transmission (Bordi and Ugolini, 1999; Nakanishi 
and Masu, 1994). Additionally, these receptors also have been implicated in a number of 
neurodegenerative diseases such as amyotrophic lateral sclerosis, Huntington’s and 
Alzheimer’s disease (Ribeiro et al., 2010a). Regulation of these receptors is a dynamic 
process involving many interacting proteins and scaffolding complexes (Enz, 2012). We 
have identified CaMKIIα as a novel IL2-interacting protein of Group I mGluRs. Our 
results reveal the following: 1) the interaction between CaMKIIα and mGluR5 is 
independent of CaMKIIα activity 2) CaMKIIα decreases mGluR5-mediated ERK1/2 
phosphorylation, but not IP3 formation or Ca2+ release, 3) CaMKIIα binding to mGluR5 
is increased in the presence of Aβ42 oligomers, and 4) Aβ42 oligomers can activate 
mGluR5-mediated ERK1/2 in a PKC dependent manner. 
 
4.1 CAMKIIα interacts with mGluR5 independent of CAMKIIα activity.  
 
Compared to prototypic GPCRs, the Group I mGluRs have small intracellular 
loops and a large C-tail which harbours many interacting proteins (Enz, 2012). 
Interestingly, C-tail interacting proteins such as GRK2, Pyk2 and CAIN can also interact 
with the second intracellular loop (Dhami et al., 2005; Nicodemo et al., 2010; Ferreira et 
al., 2009). This ability may result in differential outcomes in the regulation of these 
receptors. For example, the mGluR1a and mGluR1b splice variants reveal subtle 
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differences the attenuation of mGluR1 signaling by GRK2 (Dhami et al., 2005). 
In a proteomic screen, we have identified CaMKIIα as a novel IL2 interacting 
protein of Group I mGluRs. The IL2 is also able to interact with the other CNS abundant 
CaMKII isoform, CaMKIIβ. Τhe association between CaMKIIα and Group I mGluRs 
appears to be a direct interaction, since we have shown that the second intracellular loop 
peptide is sufficient for this interaction to occur. Additionally, CaMKIIα has been shown 
to interact with mGluR1 through the C-terminus tail demonstrating once more that 
interacting proteins of Group I mGluRs have multiple sites for interaction (Jin et al., 
2013a).  More specifically, this group found that CaMKIIα interacts with the proximal C-
tail of mGluR1a and the interaction is localized between the residues K841 and N885 (Jin 
et al., 2013a). As a serine/threonine kinase, many binding partners of CaMKIIα are 
phosphorylation substrates. The region in mGluR1a that mediates CaMKIIα binding 
contains the CaMKIIα substrate recognition motif, RXXT (Jin et al., 2013a; White et al., 
1998) and can be phosphorylated by CaMKIIα. mGluR5 also contains several CaMKII 
substrate recognition motifs. However whether they are phosphorylated by CaMKIIα is 
unknown. Therefore, future experiments are needed to determine if CaMKIIα 
phosphorylates mGluR5 and whether phosphorylation by CaMKIIα contributes to 
receptor regulation.  
Another important characteristic of the interaction between mGluR5 and 
CaMKIIα is whether mGluR5 can bind to the activated form of CaMKIIα. Jin et al., 
(2013a) showed using in vitro assays that the presence of Ca2+ activates CaMKIIα and 
activated CaMKIIα has a higher affinity for mGluR1 as it displays greater binding to the 
receptor than the inactivated form. In addition, activated CaMKIIα has been shown to 
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increase the affinity for many targets including the D3 dopamine receptor and M4 
muscarinic receptor (Liu et al., 2010; Guo et al., 2011). Moreover, the activation of 
CaMKIIα results in translocation from the cytoplasm to the post-synaptic density where it 
binds to the NMDA receptor and facilitates LTP (Strack et al., 1997). Thus, activation of 
CaMKIIα represents an important mechanism by which the kinase can regulate its 
association with binding partners.  In contrast to these studies, we found that treatment 
with the CAMKIIα inhibitor KN-93 does not result in any difference in the amount of 
CaMKIIα co-immunoprecipitated with mGluR5a. This, along with the result that the 
interaction between CaMKIIα mGluR5 is independent of receptor activation, indicates 
that the association between CaMKIIα and mGluR5 is independent of CaMKIIα activity. 
When two molecules of Ca2+/CaM bind to two subunits of CaMKIIα, 
autophosphorylation of the enzyme can occur. CaMKIIα autophosphorylation results in 
persistent activity of CaMKIIα even after Ca2+/CaM is no longer bound (Hanson and 
Schulman, 1992). The inhibitor KN-93 works by interacting with the Ca2+/CaM binding 
site on CaMKIIα to prevent its activation by Ca2+/CaM. However, this inhibitor does not 
prevent autophosphorylation of the kinase (Sumi et al., 1991). CaMKIIα 
autophosphorylation has been shown to lead to increased binding to the D3 dopamine 
receptor (Liu et al., 2010). It would be interesting to see whether autophosphorylated 
CaMKIIα interacts with mGluR5 and whether autophosphorylation of CaMKIIα 
contributes in the regulation of mGluR5. 
 
4.2 Regulation of  mGluR5 signaling by CaMKIIα 
Interacting proteins of Group I mGluRs can be categorized according to the roles 
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they play such as scaffolding, cytoskeletal regulation and signaling. In the present study, 
we looked at the effects of CaMKIIα on mGluR5 signaling. It is well established that 
activation of Group I mGluRs activates the heterotrimeric Gαq/11 protein which leads to 
formation of IP3 and Ca2+ release from intracellular stores. Jin and coworkers (2013a) 
established a role for CaMKIIα in regulating mGluR1-mediated IP formation in rat 
striatal slices. They found that blocking the interaction between mGluR5 and CaMKIIα 
by a Tat interference peptide results in a reduced desensitization response to DHPG. We 
previously showed that overexpression of CAMKIIα in HEK293 cells does not affect 
mGluR1a-mediated IP formation. However, this difference may be attributed to the 
differences between HEK293 cells and rat striatal neurons. In this study, we show that 
overexpression of CaMKIIα has no effect on mGluR5-mediated IP formation, but 
whether this occurs in neurons is unknown and represents an area for future study.   
When looking at Ca2+ signaling, we observed no significant effect of CaMKIIa on 
mGluR5-mediated Ca2+ release despite the tendency for Ca2+ release and the frequency of 
Ca2+ oscillations to be increased in the presence of CaMKIIα. The number of Ca2+ 
oscillations is shown to be affected by the amount of cell surface receptor (Nash et al., 
2002; Choi et al., 2011). A study in Chinese Hamster Ovary cells comparing the ability of 
receptor density and agonist concentration to affect mGluR5-mediated Ca2+ oscillations 
found that Ca2+ oscillation frequency is affected by receptor density and not agonist 
concentration (Nash et al., 2002).  In support of this, mGluR5 induced Ca2+ oscillations 
are to be affected by CaM, an interacting protein that affects cell surface expression of 
mGluR5 (Choi et al., 2011). This group found that a mutant form of mGluR5 that 
disrupts CaM binding results in reduced cell surface expression, as well as reduced 
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frequency of Ca2+ oscillations. We have previously established that mGluR1 cell surface 
expression is unaffected by CaMKIIα. However, whether CaMKIIα affects mGluR5 cell 
surface expression is unknown. It is likely, that CaMKIIα has no effect on mGluR5 cell 
surface expression since both IP and Ca2+ seem to be unaffected CaMKIIα.   
As previously mentioned, Group I mGluRs can also activate the ERK1/2 
signaling cascade by a variety of mechanisms. CaMKII has been shown to affect DHPG-
mediated ERK phosphorylation in striatal neurons (Choe and Wang, 2001). They found 
that treatment with the CaMKII inhibitor, KN-62, results in attenuation of DHPG-
induced ERK phosphorylation in the rat striatum. DHPG can activate both mGluR1 and 
mGluR5, however this study did not determine the relative contribution of ERK 
phosphorylation caused by each receptor. We found that overexpression of CaMKIIα 
results in the attenuation of mGluR5-mediated ERK1/2 phosphorylation without affecting 
IP formation or Ca2+ release. This indicates that the regulation of mGluR5 by CaMKIIα 
may involve the participation of scaffolding proteins that selectively couple the receptor 
to distinct signaling pathways. This is similar to the effect produced by biased GPCRs 
ligands that activate select downstream signaling pathways (Luttrell and Kenakin, 2011).  
 
4.3 Regulation of mGluR5 by Aβ  oligomers 
Soluble Aβ is a key player in the early pathogenesis of Alzheimer’s disease. One 
of the proposed mechanisms of Aβ-mediated toxicity involves the disturbance of Ca2+ 
homeostasis (Khachaturian ZS, 1989; Green et al., 2009; Berridge MJ, 2010). Aβ has 
been shown to affect Ca2+ signaling in a manner dependent on mGluR5 (Renner et al., 
2010; Grolla et al., 2013, Um et al., 2013). In hippocampal astrocytes, Aβ oligomer 
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treatment increases DHPG-mediated Ca2+ release (Grolla et al., 2013). Aβ oligomers can 
act as extracellular scaffolds of mGluR5 to reduce mobility and induce clustering of the 
receptor. This effect as well as mimicking clustering by artificial cross-linking leads to 
increased Ca2+ signaling in hippocampal neurons (Renner et al., 2010).  Additionally, 
Aβ induced mGluR5-mediated Ca2+ signaling has been found by Um and coworkers 
(2013) to occur in a manner that is dependent on PrPC.   
In addition to inducing Ca2+ release, Aβ signaling can also lead to ERK1/2 
activation. Chong et al., (2006) found that ERK1/2 can be activated by Aβ oligomers in a 
time and dose-dependent manner in rat hippocampal slices. Aβ oligomer-mediated 
ERK1/2 activation can also occur in SH-SY5Y cells via the α-7 nicotinic acetylcholine 
receptor (Young et al., 2009). We show that ERK1/2 activation can occur in HEK293 
cells transfected with mGluR5 in response to stimulation with 100 nM Aβ42 oligomers. 
Furthermore, we found that treating cells with a PKC inhibitor prevented the ERK1/2 
activation induced by Aβ42 oligomers suggesting that Aβ42 oligomer-induced ERK1/2 
activation is PKC-dependent. The role of ERK1/2 activation in Alzheimer’s disease is 
unclear. Some studies implicate ERK1/2 in the hyperphosphorylation of tau, a major 
hallmark of Alzheimer’s disease, but this involvement is still controversial (Drewes et al., 
1992; Ledesma et al., 1992; Lu et al., 1993; Pei et al., 2002). Additionally, we found that 
CaMKIIα overexpression does not have any appreciable effect on Aβ induced ERK1/2 
activation as it did by conventional mGluR5 activation with quisqualate. This indicates 
that Aβ oligomers can differentially regulate mGluR5 signaling: while CaMKIIα  appears 
to affect agonist-induced mGluR5 signaling, it does not appear to affect Aβ42 induced 
signaling  (Summarized in Figure 4.1).  
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We also show that the presence of Aβ42 oligomers results in increased binding of 
CaMKIIα to mGluR5. As previously mentioned Aβ42 oligomers act as an extracellular 
scaffold for mGluR5 and thus can cause clustering of mGluR5 and reduce receptor 
mobility similar to that of artificially cross-linking the receptor (Renner et al., 2010). It is 
possible that the clustering of mGluR5 induced by Aβ42 oligomers can stabilize the 
interaction with CaMKIIα, thus leading to increased co-immunoprecipitated CAMKIIα to 
the receptor. To test this hypothesis, we could examine whether artificially cross-linking 
the receptor produces an increase in co-immunoprecipitated CaMKIIα with mGluR5. 
Interestingly, receptor cross-linking is a necessary step in the co-immunoprecipitation of 
some GPCR interacting proteins (Hall RA, 2004). Both Aβ42 oligomers and mGluR5 are 
involved in the pathogenesis of Alzheimer’s disease (Selkoe, 2006; Hamilton et al., 
2014). The regulation of mGluR5 by Aβ42 oligomers represents an area of future study 
in understanding how these two players contribute to the pathogenesis of Alzheimer’s 
disease.  
 
4.4 Role of CAMKIIα and mGluR5 in synaptic plasticity 
LTP and LTD are well established forms of synaptic plasticity underlying 
memory and learning processes (Malenka and Bear, 2004).  As previously mentioned, 
translocation of activated CaMKIIα to the PSD and binding to the NMDA receptor is 
important for LTP induction (Shen and Meyer, 1999). Additionally, NMDA dependent 
LTP in the CA1 region of the hippocampus is shown to involve mGluR5 and several 
studies indicate that mGluR5 is involved in late phase LTP, a form of synaptic plasticity  
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Figure 4.1 Schematic model of mGluR5 signaling. mGluR5 activation results in 
activation of PLC, IP3 formation, Ca2+ release from intracelluar stores and PKC 
activation followed by ERK1/2 phosphorylation. mGluR5 acts as an extracellular 
scaffold for the Aβ oligomer-PrPC complex which allows for intracellular Ca2+ signaling. 
Ca2+ can activate PKC leading to ERK1/2 phosphorylation. We show that 
Aβ42 oligomers can activate mGluR5-dependent ERK1/2 phosphorylation in a PKC-
dependent manner. CaMKIIα interacts with mGluR5 to attenuate agonist-stimulated 
ERK1/2 phosphorylation but not Aβ42−stimulated ERK1/2 phosphorylation however the 
exact mechanisms are unknown.  
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dependent on protein synthesis (Lu et al., 1997, Fransesconi et al., 2004). Both CaMKIIα 
and mGluR5 play an important role in LTP however how the interaction between 
CaMKIIα and mGluR5 plays a role in LTP is unknown and would be a key future area of 
study. Interestingly, mGluR5-dependent LTD may be attenuated by activation of CaMKII 
(Huang et al., 2013). This study showed that CaMKIIα activation resulted in the 
phosphorylation of Homer1b/c, thus impairing its interaction with mGluR5. 
Consequently, the disruption of this interaction attenuates mGluR5-mediated LTD 
(Huang et al., 2013).  A direct role for CaMKIIα on mGluR5-dependent potentiation of 
NMDA receptors  has been proposed by (Jin et al., 2013b). In this study, mGluR5-
mediated Ca2+ release results in the dissociation of C-tail bound CaMKIIα and 
recruitment to the NMDA receptor where it can phosphorylate the NR2B subunit, thereby 
possibly effecting LTP (Jin et al., 2013b). 
 
4.5 Summary 
 
 In summary, we have shown here that CaMKIIα can associate with mGluR5 
independent of CaMKIIα activity. We demonstrated that CaMKIIα attenuates mGluR5-
mediated ERK1/2 phosphorylation in the absence of attenuated mGluR5-mediated IP3 
formation and Ca2+ release. Furthermore, we report that Aβ oligomers can increase 
binding of CaMKIIα to mGluR5 and can activate mGluR5-mediated ERK1/2 
phosphorylation. Group I mGluRs are not only important for learning and memory but 
also for their contribution to neurodegenerative diseases. Therefore, understanding the 
mechanisms by which Group I mGluRs can be regulated can provide us with novel 
therapeutic targets to treat neurodegenerative diseases. 
 
 
59 
REFERENCE LIST 
 
Abe, T., Sugihara, H., Nawa, H., Shigemoto, R., Mizuno, N., and Nakanishi, S. (1992). 
Molecular characterization of a novel metabotropic glutamate receptor mGluR5 coupled 
to inositol phosphate/Ca2+ signal transduction. The Journal of biological chemistry 267, 
13361-13368. 
 
Adomeit A, Graness A, Gross S, Seedorf K, Wetzker R, Liebmann C. (1999) Bradykinin 
B2 receptor-mediated mitogen-activated protein kinase activation in COS-7 cells requires 
dual signaling via both protein kinase C pathway and epidermal growth factor receptor 
transactivation. Molecular and Cellular Biology 19, 5289–5297. 
 
Aiba, A., Kano, M., Chen, C., Stanton, ME., Fox, GD., Herrup, K., Zwingman, TA., and 
Tonegawa, S. (1994). Deficient cerebellar long-term depression and impaired motor 
learning in mGluR1 mutant mice. Cell 79, 377–388. 
 
Ango, F., Prezeau, L., Muller, T., Tu, JC., Xiao, B., Worley, PF., Pin, JP, Bockaert, J., 
and Fagni, L. (2001). Agonist-independent activation of metabotropic glutamate recep- 
tors by the intracellular protein Homer. Nature  411, 962–965. 
 
Anwyl, R. (2009). Metabotropic glutamate receptor-dependent long-term potentiation. 
Neuropharmacology 56. 
 
Ashley, CT., Wilkinson, KD., Reines, D., and Warren, ST. (1993). FMR1 protein: 
conserved RNP family domains and selective RNA binding. Science 262, 563-566. 
 
Attucci, S., Carla, V., Mannaioni, G., and Moroni, F. (2001). Activation of type 5 
metabo- tropic glutamate receptors enhances NMDA responses in mice cortical wedges. 
British Journal of Pharmacology 132, 799–806. 
  
Ayala, JE., Chen, Y., Banko, JL., Sheffler, DJ., Williams, R., Telk, AN., Watson, NL., 
Xiang, Z., Zhang, Y., Jones, PJ., Lindsley, CW., Olive, MF., and Conn PJ. (2009). 
mGluR5 positive allosteric modulators facilitate both hippocampal LTP and LTD and 
enhance spatial learning. Neuropsychopharmacology 34, 2057–2071. 
 
Balschun, D., Manahan-Vaughan, D., Wagner, T., Behnisch, T., Reymann, K. G., and 
Wetzel, W. (1999). A specific role for group I mGluRs in hippocampal LTP and 
hippocampus-dependent spatial learning. Learn. Mem. 6, 138–152. 
 
Barria, A., and Malinow, R. (2005). NMDA receptor subunit composition controls 
synaptic plasticity by regulating binding to CaMKII. Neuron 48, 289-301. 
 
Bats, C., Groc, L., and Choquet, D. (2007). The interaction between Stargazin and PSD-
95 regulates AMPA receptor surface trafficking. Neuron 53, 719-734. 
 
 
 
 
 
60 
Bayer, K., De Koninck, P., and Schulman, H. (2002). Alternative splicing modulates the 
frequency-dependent response of CaMKII to Ca(2+) oscillations. The EMBO journal 21, 
3590-3597. 
 
Bear, MF., Huber, KM., and Warren, ST. (2004) The mGluR theory of fragile X mental 
retardation. Trends Neuroscience 27, 370-377. 
 
Beom, S., Cheong, D., Torres, G., Caron, M.G., and Kim, K.M. (2004). Comparative 
studies of molecular mechanisms of dopamine D2 and D3 receptors for the activation of 
extracellular signal-regulated kinase. J. Biol. Chem. 279, 28304 –28314. 
 
Beqollari, D., and Kammermeier, P. (2010). Venus fly trap domain of mGluR1 functions 
as a dominant negative against group I mGluR signaling. Journal of Neurophysiology 
104, 439-448. 
 
Berridge, M. J. (2010). Calcium hypothesis of Alzheimer’s disease. Pflugers Arch. 459, 
441–449 
 
Biber, K., Laurie, DJ., Berthele, A., Sommer, B., Tolle, TR., Gebicke-Harter, PJ., van, 
CD., and Boddeke, HW. (1999). Expression and signaling of group I metabotropic 
glutamate receptors in astrocytes and microglia. Journal of Neurochemistry 72,1671-
1680. 
 
Bordi, F., and Ugolini, A. (1999). Group I metabotropic glutamate receptors: implications 
for brain diseases. Prog. Neurobiol. 59, 55-79. 
 
Butterfield, DA. (2002). Amyloid beta-peptide (1-42)-induced oxidative stress and 
neurotoxicity: implications for neurodegeneration in Alzheimer's disease brain. A review. 
Free Radic Res. 36, 1307-1313. 
 
Caraci, F., Battaglia, G., Sortino, MA., Spampinato, S., Molinaro, G., Copani, A., 
Nicoletti, F., and Bruno, V. (2012). Metabotropic glutamate receptors in 
neurodegeneration/neuroprotection: Still a hot topic? Neurochem. Int 61, 559–565. 
 
Chao, L., Stratton, M., Lee, I.-H., Rosenberg, O., Levitz, J., Mandell, D., Kortemme, T., 
Groves, J., Schulman, H., and Kuriyan, J. (2011). A mechanism for tunable 
autoinhibition in the structure of a human Ca2+/calmodulin- dependent kinase II 
holoenzyme. Cell 146, 732-745. 
 
Chen, QS., Kagan, BL.,  Hirakura, Y., and Xie, CW. (2000) Impairment of 
hippocampal long-term potentiation by Alzheimer amyloid beta-peptides. Journal of 
Neuroscience Research 60, 65-72. 
 
 
 
Choe, ES., and Wang, JQ. (2001) . Group I metabotropic glutamate receptors control 
 
 
61 
phosphorylation of CREB, Elk-1 and ERK via a CaMKII-dependent pathway in rat 
striatum. Neurosci Lett 313,129 –132. 
 
Choi, KY., Chung, S., and Roche KW (2011). Differential binding of calmodulin to 
group I metabotropic glutamate receptors regulates receptor trafficking and signaling. 
Jornal of  Neuroscience 31, 5921–5930. 
 
Chong, YH., Shin, YJ., Lee, EO., Kayed, R., Glabe, CG., and Tenner, AJ. (2006). 
ERK1/2 activation mediates Abeta oligomer-induced neurotoxicity via caspase-3 
activation and tau cleavage in rat organotypic hippocampal slice cultures. Journal of 
Biolgical Chemistry 281, 20315–20325. 
 
Choquet, D. (2010). CaMKII triggers the diffusional trapping of surface AMPARs 
through phosphorylation of stargazin. Neuron 67, 239-252. 
 
Chow, VW., Mattson, M.P., Wong, P.C., and Gleichmann, M. (2009) An Overview of 
APP Processing Enzymes and Products. Neuromolecular Medicine. 
 
Chun, L., Zhang, W.-h., and Liu, J.-f. (2012). Structure and ligand recognition of class C 
GPCRs. Acta pharmacologica Sinica 33, 312-323. 
 
Cissé, M., Halabisky, B., Harris, J., Devidze, N., Dubal, DB., Sun, B., Orr, A., Lotz, G., 
Kim, DH., Hamto, P., Ho, K., Yu, GQ., Mucke, L. (2011). Reversing EphB2 depletion 
rescues cognitive functions in Alzheimer model. Nature 469, 47–52 
 
Clark, BP., Baker, SR., Goldsworthy, J., Harris, JR., and Kingston, AE. (1997) (+)-2-
Methyl-4-carboxyphenylglycine (LY367385) selectively antagonises metabotropic 
glutamate mGluR1 receptors. Bioorg. Med. Chem. Lett. 7, 2777-2780. 
 
Conn, P., and Pin, J. (1997). Pharmacology and functions of metabotropic glutamate 
receptors. Annual review of pharmacology and toxicology 37, 205-237. 
 
Dale, L., Babwah, A., Bhattacharya, M., Kelvin, D., and Ferguson, S. (2001). Spatial 
temporal patterning of metabotropic glutamate receptor-mediated inositol 1,4,5- 
triphosphate, calcium, and protein kinase C oscillations: protein kinase C-dependent 
receptor phosphorylation is not required. The Journal of biological chemistry 276, 35900- 
35908. 
 
Daub, H., Wallasch, C., Lankenau, A., Herrlich, A.,  and Ullrich, A. (1997) Signal 
characteristics of G-protein-transactivated EGF receptor. EMBO Journal 16, 7032–7044. 
 
Della  Rocca, GJ., Maudsley, S., Daaka, Y.,  Lefkowitz RJ., Luttrell LM. (1999). 
Pleiotropic coupling of G-protein-coupled receptors to the mitogen-activated protein 
kinase cascade. Role of focal adhesions and receptor tyrosine kinases. Journal of  
Biological  Chemistry 274, 13978–13984. 
 
 
 
 
62 
Dhami GK, and Ferguson SS (2006) Regulation of metabotropic glutamate re- ceptor 
signaling, desensitization and endocytosis. Pharmacol Ther 111, 260 –271. 
 
Dhami, G., Anborgh, P., Dale, L., Sterne-Marr, R., and Ferguson, S. (2002). 
Phosphorylation-independent regulation of metabotropic glutamate receptor signaling by 
G protein-coupled receptor kinase 2. The Journal of biological chemistry 277, 25266-
25272. 
 
Dhami, G., Babwah, A., Sterne-Marr, R., and Ferguson, SS. (2005). 
Phosphorylationindependent regulation of metabotropic glutamate receptor 1 signaling 
requires g proteincoupled receptor kinase 2 binding to the second intracellular loop. The 
Journal of biological chemistry 280, 24420-24427. 
 
Dhami, G., Dale, L., Anborgh, P., O'Connor-Halligan, K., Sterne-Marr, R., and Ferguson, 
S. (2004). G Protein-coupled receptor kinase 2 regulator of G protein signaling homology 
domain binds to both metabotropic glutamate receptor 1a and Galphaq to attenuate 
signaling. The Journal of biological chemistry 279, 16614-16620. 
 
Dinamarca, MC., Ríos, JA., and  Inestrosa, NC. (2012). Postsynaptic receptors for 
amyloid-β oligomers as mediators of neuronal damage in Alzheimer’s disease. Frontiers 
in Physiology 3, 464. 
 
Doherty, AJ., Palmer, MJ., Henley, JM., Collingridge, GL., and Jane, DE. (1997) 
(RS)-2-chloro-5-hydroxyphenylglycine (CHPG) activates mGlu5, but not mGlu1, 
receptors expressed in CHO cells and potentiates NMDA responses in the hippocampus. 
Neuropharmacology 36, 265-267. 
 
Dolen, G., Bear, MF. (2008) Role for metabotropic glutamate receptor 5 (mGluR5) 
in the pathogenesis of fragile X syndrome. Journal of  Physiology 586, 1503-1508. 
 
Emery, A., Pshenichkin, S., Takoudjou, G., Grajkowska, E., Wolfe, B., and Wroblewski, 
J. (2010). The protective signaling of metabotropic glutamate receptor 1 Is mediated by 
sustained, beta-arrestin-1-dependent ERK phosphorylation. The Journal of biological 
chemistry 285, 26041-26048. 
 
Enz, R. (2007) The trick of the tail: protein-protein interactions of metabo- tropic 
glutamate receptors. Bioessays 29,  60–73 
 
Enz, R. (2012) Metabotropic glutamate receptors and interacting proteins: evolving drug 
targets. Curr Drug Targets 13:145–156 
 
Enz, R. (2012). Structure of metabotropic glutamate receptor C-terminal domains in 
contact with interacting proteins. Frontiers in molecular neuroscience 5, 52. 
 
Erondu, N., and Kennedy, M. (1985). Regional distribution of type II 
Ca2+/calmodulindependent protein kinase in rat brain. The Journal of neuroscience : the 
official journal of the Society for Neuroscience 5, 3270-3277. 
 
 
 
63 
Esseltine, JL., Willard, MD., Wulur, IH., Lajiness, ME., Barber, TD., and Ferguson, SS. 
(2013). Somatic Mutations in GRM1 in Cancer Alter Metabotropic Glutamate Receptor 1 
Intracellular Localization and Signaling. Mol Pharmacol 83, 770–780 
 
Ferguson, S., and Caron, M. (2004). Green fluorescent protein-tagged beta-arrestin 
translocation as a measure of G protein-coupled receptor activation. Methods in 
molecular biology (Clifton, NJ) 237, 121-126. 
 
Ferguson, SS. (2001). Evolving concepts in G protein-coupled receptor endocytosis: the 
role in receptor desensitization and signaling. Pharmacol Rev 53, 1–24. 
 
Ferraguti, F., and Shigemoto, R. (2006). Metabotropic glutamate receptors. Cell and 
tissue research 326, 483-504. 
 
Ferraguti, F., Baldani-Guerra, B., Corsi, M., Nakanishi, S., and Corti, C. (1999). 
Activation of the extracellular signal-regulated kinase 2 by metabotropic glutamate 
receptors. The European journal of neuroscience 11, 2073-2082. 
 
Ferraguti, F., Conquet, F., Corti, C., Grandes, P, Kuhn, R., and Knopfel, T. (1998). 
Immunohistochemical localization of the metabotropic glutamate receptor mGluR1’ in 
the adult rodent forebrain. Evidence for a differential distribution of mGluR1 splice 
variants. J Comp Neurol 400, 391– 407. 
 
Ferreira, L., Dale, L., Ribeiro, F., Babwah, A., Pampillo, M., and Ferguson, S. (2009). 
Flor, PJ., Gomeza, J., Tones, MA., Kuhn, R., Pin, JP. And  Knopfel, T. (1996). Journal of  
Neurochemistry 67, 58-63. 
 
Flor, P. J., Gomeza, J., Tones, M. A., Kuhn, R., Pin, J. P. & Knopfel, T. (1996). The C-
terminal domain of the mGluR1 metabotropic glutamate receptor affects sensitivity to 
agonists. Journal of Neurochemistry 67, 58–63.  
 
Francesconi, A., and Duvoisin, R. (1998). Role of the second and third intracellular loops 
of metabotropic glutamate receptors in mediating dual signal transduction activation. The 
Journal of Biological Chemistry 273, 5615-5624. 
 
Francesconi, W., Cammalleri, M., Sanna, PP. (2004). The metabotropic glutamate 
receptor 5 is necessary for late- phase long-term potentiation in the hippocampal CA1 
region. Brain Research. 1022, 12–18. 
 
Gasparini, F., Lingenhohl, K., Stoehr, N., Flor, PJ., Heinrich, M., Vranesic, I., Biollaz, 
M., Allgeier, H., Heckendorn, R., Urwyler, S., Varney, M. A., Johnson, EC., Hess, SD., 
Rao, SP., Sacaan, AI., Santori, EM., Velicelebi, G., and Kuhn, R. (1999). 2-Methyl-6-
(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 
receptor antagonist. Neuropharmacology 38, 1493-1503. 
 
 
 
 
64 
 
Giese, K., Fedorov, N., Filipkowski, R., and Silva, A. (1998). Autophosphorylation at 
Thr286 of the alpha calcium-calmodulin kinase II in LTP and learning. Science 
279, 870-873. 
Gomeza, J., Joly, C., Kuhn, R., Knöpfel, T., Bockaert, J., and Pin, J. (1996). The second 
intracellular loop of metabotropic glutamate receptor 1 cooperates with the other 
intracellular domains to control coupling to G-proteins. The Journal of biological 
chemistry 271, 2199-2205. 
 
Green, K. N. (2009). Calcium in the initiation, progression and as an effector of 
Alzheimer’s disease pathology. J. Cell. Mol. Med. 13 2787–2799. 
 
Grolla, AA., Sim, JA., Lim, D., Rodriguez, JJ., Genazzani, AA., and Verkhratsky, A. 
(2013). Amyloid-beta and Alzheimer’s disease type pathology differentially affects the 
calcium signalling toolkit in astrocytes from different brain regions. Cell Death Dis. 9, 
623 
 
Groves, J., Schulman, H., and Kuriyan, J. (2011). A mechanism for tunable 
autoinhibition in the structure of a human Ca2+/calmodulin- dependent kinase II 
holoenzyme. Cell 146, 732-745. 
 
Gunther, EC., Strittmatter, SM. (2010). Beta-amyloid oligomers and cellular prion 
protein in Alzheimer's disease. J Mol Med (Berl) 88, 331-338. 
 
Guo, ML., Fibuch, EE., Liu, XY., Choe, ES., Buch, S., Mao, LM., and Wang, JQ. (2010). 
CaMKIIalpha interacts with M4 muscarinic receptors to control receptor and 
psychomotor function. The EMBO Journal 29, 2070-2081. 
 
Hall, RA. (2004). Co-immunoprecipitation as a strategy to evaluate receptor-receptor or 
recetptor-protein interactions. G Protein-Coupled Receptor–Protein Interactions.165-178 
 
Hamilton, A., Esseltine, JL., DeVries RA., Cregan SP., and Ferguson, SS. (2014). 
Metabotropic glutamate receptor 5 knockout reduces cognitive impairment and 
pathogenesis in a mouse model of Alzheimer's disease. Molecular Brain 7, 40. 
 
Hanson, PI.,  and Schulman, H.(1992). Neuronal Ca2+/calmodulin-dependent protein 
kinases. Annual Reviews Biochemistry 61, 559-661. 
 
Hardy J, Selkoe DJ. (2002). The amyloid hypothesis of Alzheimer's disease: progress and 
problems on the road to therapeutics. Science 297, 353–356. 
 
Hishinuma, S.,  and Ogura, K. (2000). Ca2+/Calmodulin-Mediated Regulation of the 
Desensitizing Process in Gq Protein-Coupled Histamine H1 Receptor-Mediated Ca2+ 
Responses in Human U373 MG Astrocytoma Cells. Journal of Neuro Chemistry 75, 772-
781. 
 
 
65 
 
Holtzman, DM., Morris, JC., and Goate, AM. (2011). Alzheimer's disease: the challenge 
of the second century. Science Translational Medicine 3, 77. 
 
Hsieh, H., Boehm, J., Sato, C., Iwatsubo, T., Tomita, T., Sisodia, S., and Malinow, R. 
(2006). AMPAR removal underlies Abeta-induced synaptic depression and dendritic 
spine loss. Neuron 52, 831–843 
 
Hudmon, A., and Schulman, H. (2002). Neuronal CA2+/calmodulin-dependent protein 
kinase II: the role of structure and autoregulation in cellular function. Annual review of 
biochemistry 71, 473-510. 
 
Jia, Z., Lu, YM., Henderson, J., Taverna, F., Romano, C., Abramow-Newerly, W., 
Wojtowicz, M., and Roder J.(1998). Selective Abolition of the NMDA Component of 
Long-Term Potentiation in Mice Lacking mGluR5. Learning and Memory 5, 331-343. 
 
Jin, DZ., Guo, ML., Xue, B., Fibuch, EE., Choe, ES., Mao, LM., and Wang, JQ. (2013a). 
Phosphorylation and feedback regulation of metabotropic glutamate receptor 1 by 
calcium/calmodulin-dependent protein kinase II. Journal of Neuroscience 33, 3402-3412. 
 
Jin, DZ., Guo, ML., Xue, B., Mao, LM., and Wang, JQ. (2013b). Differential regulation 
of CaMKIIα interactions with mGluR5 and NMDA receptors by Ca2+ in neurons. 
Journal of Neurochemistry 127, 620-631. 
 
Joly, C., Gomeza, J., Brabet, I., Curry, K., Bockaert, J., and Pin, J. (1995). Molecular, 
functional, and pharmacological characterization of the metabotropic glutamate receptor 
type 5 splice variants: comparison with mGluR1. The Journal of neuroscience : the 
official journal of the Society for Neuroscience 15, 3970-3981. 
 
Jong, YJ., Kumar, V., and O’Malley, KL. (2009). Intracellular metabotropic glutamate 
receptor 5 (mGluR5) activates signaling cascades distinct from cell surface counterparts. 
Journal of Biological Chemistry 284, 35827–35838. 
 
Karim, F., Wang, C., and Gereau, R. (2001). Metabotropic glutamate receptor subtypes 1 
and 5 are activators of extracellular signal-regulated kinase signaling required for 
inflammatory pain in mice. The Journal of neuroscience: the official journal of the 
Society for Neuroscience 21, 3771-3779. 
 
Kawabata, S., Kohara, A., Tsutsumi, R., Itahana, H., Hayashibe, S., Yamaguchi, T., and 
Okada, M. (1998). Diversity of calcium signaling by metabotropic glutamate receptors. 
The Journal of biological chemistry 273, 17381-17385. 
 
Kellett, KAB., and Hooper, NM. (2009). Prion protein and Alzhemier Disease. Prion 3, 
190-194. 
 
Khachaturian ZS.(1989). Calcium, membranes, aging, and Alzheimer’s disease. 
introduction and overview. Ann N Y Acad Sci. 9, 1–4. 
 
 
66 
 
Kumar V., Fahey PG., Jong YJ., Ramanan N., and O’Malley K. L. (2012). Activation of 
intracellular metabotropic glutamate receptor 5 in striatal neurons leads to up-regulation 
of genes associated with sustained synaptic transmission including Arc/Arg3.1 protein. 
Journal of Biological Chemistry 287, 5412–5425 
 
Kunishima, N., Shimada, Y., Tsuji, Y., Sato, T., Yamamoto, M., Kumasaka, T., 
Nakanishi, S., Jingami, H., and Morikawa, K. (2000). Structural basis of glutamate 
recognition by a dimeric metabotropic glutamate receptor. Nature 407, 971-977. 
 
Lagerström, M., and Schiöth, H. (2008). Structural diversity of G protein-coupled 
receptors and significance for drug discovery. Nature Review Drug Discovery 4, 339-
357. 
 
Lauren, J., Gimbel, DA., Nygaard, HB., Gilbert, JW., and Strittmatter, SM. (2009). 
Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta 
oligomers. Nature 457, 1128-1132. 
 
Lee, H., Barbarosie, M., Kameyama, K., Bear, M., and Huganir, R. (2000). Regulation of 
distinct AMPA receptor phosphorylation sites during bidirectional synaptic plasticity. 
Nature 405, 955-959. 
 
Lee, H., Zhu, X., O, M., and Webber, K. (2004). The role of metabotropic glutamate 
receptors in Alzheimer's disease. Acta. Neurobiol. 64, 89-98. 
 
Lee, JH., Lee, J., Choi, KY., Hepp, R., Lee, J. Y., Lim, MK., Chatani-Hinze, M., Roche, 
PA., Kim, DG., Ahn, YS., Kim, CH., and Roche, KW. (2008). Calmodulin dynamically 
regulates the trafficking of the metabotropic glutamate receptor mGluR5. PNAS 105, 
12575–12580. 
 
Lee, S.-J.R., Escobedo-Lozoya, Y., Szatmari, E., and Yasuda, R. (2009). Activation of 
CaMKII in single dendritic spines during long-term potentiation. Nature 458, 299-304. 
 
Lee, YS.,  and Silva, A. (2009) The molecular and cellular biology of enhanced 
cognition. Nature Review Neuroscience 10, 126–140. 
 
Leonard, AS., Lim, IA., Hemsworth, DE., Horne, MC., Hell, JW. (1999). 
Calcium/calmodulin-dependent protein kinase II is associated with the N-methyl-D-
aspartate receptor. PNAS 96, 3239–3244. 
 
Li, S., Hong, S., Shepardson, N.E., Walsh, DM., Shankar, G.M., and Selkoe, D. (2009). 
Soluble oligomers of amyloid Beta protein facilitate hippocampal long-term depression 
by disrupting neuronal glutamate uptake. Neuron 62, 788-801. 
 
Linden, R., Martins, VR., Prado, MA., Cammarota, M., Izquierdo, I., Brentani, RR. 
(2008). Physiology of the prion protein. Physiology Review 88, 673-728. 
 
 
67 
 
Lisman, J., Schulman, H., and Cline, H. (2002). The molecular basis of CaMKII 
functionin synaptic and behavioural memory. Nature reviews Neuroscience 3, 175-190. 
 
 
Lisman, J., Yasuda, R., and Raghavachari, S. (2012). Mechanisms of CaMKII action in 
long-term potentiation. Nature reviews Neuroscience 13, 169-182. 
 
Liu XY, Mao LM, Zhang GC, Papasian CJ, Fibuch EE, Lan HX, Zhou HF, Xu M, Wang 
JQ (2009). Activity-dependent modulation of limbic dopamine D3 receptors by CaMKII. 
Neuron 61, 425– 438. 
 
Lu, YM., Jia, Z., Janus, C., Henderson, J., Gerlai, R., Wojtowicz, M., and Roder J.(1997) 
Mice lacking metabotropic glutamate receptor 5 show impaired learning and reduced 
CA1 long-term potentiation (LTP), but normal CA3-LTP. Journal of Neuroscience 17, 
5196–5205. 
 
Lucchesi, W., Mizuno, K., and Giese, K. (2011). Novel insights into CaMKII function 
and regulation during memory formation. Brain research bulletin 85, 2-8. 
 
Lujan R., N., Z., Roberts, J. D., Shigemoto, R., Somogyi, P. (1996). Perisynaptic location 
of metabotropic glutamate receptors mGluR1 and mGluR5 on dendrites and dendritic 
spines in the rat hippocampus. European journal of neuroscience 8, 1488-1500. 
Luttrell LM, Kenakin TP. Refining efficacy: allosterism and bias in G protein-coupled 
receptor signaling. Methods Mol Biol (2011). 756, 3–3510. 
 
Luttrell, LM., and Lefkowitz, RJ. (2002). The role of beta-arrestins in the termination and 
transduction of G-protein-coupled receptor signals. J Cell Sci 115, 455–465. 
 
Luttrell LM, Ferguson SS, Daaka Y, Miller WE, Maudsley S, Della Rocca GJ, Lin F, 
Kawakatsu H, Owada K, Luttrell DK, Caron MG, Lefkowitz RJ. (1999). Beta-arrestin-
dependent formation of beta2 adrenergic receptor-Src protein kinase complexes. Science 
283, 655–6110. 
 
Luttrell, LM., Roudabush, FL., Choy, EW., Miller, WE., Field, ME., Pierce, KL., 
Lefkowitz, RJ. (2001). Activation and targeting of extracellular signal-regulated kinases 
by β-arrestin scaffolds. PNAS 98, 2449-2454. 
 
Lynch, M. (2004). Long-term potentiation and memory. Physiological Reviews 84, 87-
136. 
 
López-Bendito, G., Shigemoto, R., Fairén, A., and Luján, R. (2002). Differential 
distribution of group I metabotropic glutamate receptors during rat cortical development. 
Cerebral cortex 12, 625-638. 
 
 
 
68 
 
Lüscher, C., and Huber, K. (2010) Group 1 mGluR-dependent long-term depression 
(mGluR-LTD): mechanism and implications for circuitry and disease. Neuron 65, 445-
459. 
 
Macey, TA., Lowe, JD., and Chavkin, C. (2006). Mu opioid receptor activation of 
ERK1/2 is GRK3 and arrestin dependent in striatal neurons. Journal of Biological 
Chemistry 281, 34515-34524. 
 
Malinow, R. (2003). AMPA receptor trafficking and long-term potentiation. Philos Trans 
R Soc Lond B Biol Sci 358, 707–714. 
 
Malenka, R., and Bear, M. (2004). LTP and LTD: an embarrassment of riches. Neuron 
44, 5-21. 
 
Malinow R. (2003). AMPA receptor trafficking and long-term potentiation. Philos. 
Trans. R. Soc. Lond. B. Biol. Sci. 358, 707–714. 
 
Mao, L., Yang, L.,Tang, Q., Samdani, S., Zhang, G., and Wang, JQ. (2005a). The 
scaffold protein Homer1b/c links metabotropic glutamate receptor 5 to extracellular 
signal-regulated protein kinase cascades in neurons. Journal of Neuroscience 25, 2741-
2752. 
 
Mao, L., Yang, L., Arora, A., Choe, ES., Zhang, G., Liu, Z., Fibuch, EE., and Wang, JQ. 
(2005b). Role of protein phosphatase 2A in mGluR5-regulated MEK/ERK 
phosphorylation in neurons. Journal of  Biological  Chemistry 280, 12602-12610. 
 
Mao, L., Liu, X., Zhang, G., Chu X., Fibuch, E., Wang, L., Liu, Z., and Wang JQ. (2008). 
Phosphorylation of group I metabotropic glutamate receptors (mGluR1/5) in vitro and in 
vivo. Neuropharmacology 55, 403-408. 
 
Mockett, B., Guévremont, D., Wutte, M., Hulme, S., Williams, J., and Abraham, W. 
(2011). Calcium/calmodulin-dependent protein kinase II mediates group I metabotropic 
glutamate receptor-dependent protein synthesis and long-term depression in rat 
hippocampus. The Journal of neuroscience : the official journal of the Society for 
Neuroscience 31, 7380-7391. 
 
Mundell, S., Matharu, A.-L., Pula, G., Holman, D., Roberts, P., and Kelly, E. (2002). 
Metabotropic glutamate receptor 1 internalization induced by muscarinic acetylcholine 
receptor activation: differential dependency of internalization of splice variants on 
nonvisual arrestins. Molecular pharmacology 61, 1114-1123. 
Nakanishi, S. (1992). Molecular diversity of glutamate receptors and implications for 
brain function. Science 258, 597-603. 
 
Nakanishi, S., and Masu, M. (1994). Molecular diversity and functions of glutamate 
receptors. Annu. Rev. Biophys. Biomol. Struct. 23, 319-348. 
 
 
69 
 
Nash MS, Schell MJ, Atkinson PJ, Johnston NR, Nahorski SR, Challiss RA. (2002). 
Determinants of metabotropic glutamate receptor-5-mediated Ca2+ and inositol 1,4,5-
trisphosphate oscillation frequency: receptor density versus agonist concentration. J Biol 
Chem 277, 35947–35960 
 
Neer, EJ. (1995). Heterotrimeric G proteins: Organizers of Transmembrane Signals. Cell 
80, 249-257. 
 
Nelson, P.T., Braak, H., and Markesbery, W.R. (2009) Neuropathology and cognitive 
impairment in Alzheimer disease: a complex but coherent relationship. J. Neuropathol. 
Exp. Neurol. 68, 1–14. 
 
Neyman, S., and Manahan-Vaughan, D. (2008). Metabotropic glutamate receptor 1 
(mGluR1) and 5 (mGluR5) regulate late phases of LTP and LTD in the hippocampal 
CA1 region in vitro. European Journal of Neuroscience  6, 1345-1352. 
 
Nicodemo, A., Pampillo, M., Ferreira, L., Dale, L., Cregan, T., Ribeiro, F., and Ferguson, 
S. (2010). Pyk2 uncouples metabotropic glutamate receptor G protein signaling but 
facilitates ERK1/2 activation. Molecular Brain 3, 4. 
 
Nicoletti, F., Bruno,V., Catania, MV., Battaglia, G., Copani, A., Barbagallo, G., Cena, 
V., Sanchez-Prieto, J., Spano,  PF., and Pizzi, M. (1999). Group-I Metabotropic 
Glutamate Receptors: Hypotheses to Explain Their Dual Role in Neurotoxicity and 
Neuroprotection. Neuropharmacology 38, 1477–1484. 
 
Niswender, C.M., and Conn, P.J. (2010). Metabotropic glutamate receptors: phsyiology, 
pharmacology, and disease. Annu. Rev. Pharmacol. Toxicol. 50, 295-322. 
 
Opazo, P., Labrecque, S., Tigaret, C., Frouin, A., Wiseman, P., De Koninck, P., and 
Choquet, D. (2010). CaMKII triggers the diffusional trapping of surface AMPARs 
through phosphorylation of stargazin. Neuron 67, 239-252. 
 
Ozawa S, Kamiya H, Tsuzuki K. (1998). Glutamate receptors in the mammalian central 
nervous system. Progress in Neurobiology. 54, 581–618. 
 
Pearson, G., Robinson, F., Beers Gibson, T., Xu, BE., Karandikar, M., Berman, K. and 
Cobb, MH. (2001). Mitogen-activated protein (MAP) kinase pathways: regulation and 
physiological functions. Endocrine Review 22, 153–183. 
 
Peavy, RD., Chang, MS., Sanders-Bush, E., and Conn, PJ. (2001). Metabotropic 
glutamate receptor 5-induced phosphorylation of extracellular signal-regulated 
kinase in astrocytes depends on transactivation of the epidermal growth factor 
receptor. Journal of Neuroscience 21, 9619-9628. 
 
 
 
 
70 
 
Pieretti, M., Zhang, FP., Fu, YH., Warren, ST., Oostra BA., Caskey, CT.,  and Nelson 
DL. (1991). Absence of expression of the FMR-1 gene in Fragile X syndrome. Cell 66, 
817–822. 
 
Pin, J.P., and Duvoisin R. (1995). The metabotropic glutamate receptors: structure and 
function. Neuropharmacology 34, 1-26. 
 
Poncer, JC.,  Esteban, JA., and Malinow, R. (2002). Multiple mechanisms for the 
potentiation of AMPA receptor-mediated transmission by alpha- Ca21/Calmodulin-
dependent protein kinase II. Journal of Neuroscience 22, 4406– 4411. 
 
Renner M, Lacor PN, Velasco PT, Xu J, Contractor A, Klein WL, Triller A. (2010). 
Deleterious effects of amyloid beta oligomers acting as an extracellular scaffold for 
mGluR5. Neuron 66, 739-754. 
 
Ribeiro FM, Ferreira LT, Paquet M, Cregan T, Ding Q, Gros R, Ferguson SSG. (2009). 
Phosphorylation-independent regulation of metabotropic glutamate receptor 5 
desensitization and internalization by G protein-coupled receptor kinase 2 in neurons. J 
Biol Chem 7, 23444–23453. 
 
Ribeiro, FM., Paquet, M., Cregan, SP., and Ferguson, SSG. (2010a). Group 1 
metabotropic glutamate receptor signaling and its implication in neurological disease. 
CNS Neurol Discord Drug Targets 9, 574–595. 
 
Ribeiro, F., Paquet, M., Ferreira, L., Cregan, T., Swan, P., Cregan, S., and Ferguson, S. 
(2010b). Metabotropic glutamate receptor-mediated cell signaling pathways are altered in 
a mouse model of Huntington's disease. The Journal of neuroscience : the official journal 
of the Society for Neuroscience 30, 316-324. 
 
Ribeiro, F., Pires, R., and Ferguson, S. (2011). Huntington's disease and Group I 
metabotropic glutamate receptors. Molecular neurobiology 43, 1-11. 
 
Riedel G, Reymann KG. (1996). Metabotropic glutamate receptors in hippocampal long-
term potentiation and learning and memory. Acta Physiol. Scand 157, 1–19 
 
Romano, C., Sesma, M., McDonald, C., O'Malley, K., Van den Pol, A., and Olney, J. 
(1996). Distribution of metabotropic glutamate receptor mGluR5 immunoreactivity in rat 
brain. The Journal of comparative neurology 355, 455-469. 
 
Roskoski R., Jr. ERK1/2 MAP kinases: structure, function, and regulation. (2012) 
Pharmacology Research 66, 105–143. 
 
Schiefer, J., Sprunken, A., Puls, C., Luesse, H.G., Milkereit, A., Milkereit, E., Johann, V., 
and Kosinski, CM. (2004). The metabotropic glutamate receptor 5 antagonist MPEP and 
the mGluR2 agonist LY379268 modify disease progression in a transgenic mouse model 
 
 
71 
of Huntington's disease. Brain Research 1019, 246-254. 
 
Schnell. E., Sizemore, M., Karimzadegan, S.,  Chen, L., Bredt, DA., and Nicoll, RA. 
Direct interactions between PSD-95 and stargazin control synaptic AMPA receptor 
number. (2002) PNAS 99, 13902-13907. 
 
Schools, GP., and Kimelberg, HK. (1999). mGluR3 and mGluR5 are the predominant 
metabotropic glutamate receptor mRNAs expressed in hippocampal astrocytes 
acutely isolated from young rats. Journal of Neuroscience Research 58, 533-543. 
 
Selkoe, DJ. (2006). Toward a comprehensive theory for Alzheimer’s disease. Hypothesis: 
Alzheimer's disease is caused by the cerebral accumulation and cytotoxicity of amyloid 
β-protein. Ann NY Acad Sci 924, 17-25. 
 
Seo, B., Choy EW., Maudsley, S., Miller, WE., Wilson, BA., and L uttrell, LM. (2000) 
Pasteurella multocida toxin stimulates mitogen-activated protein kinase via Gq/11-
dependent transactivation of the epidermal growth factor receptor. Journal of  Biological  
Chemistry 275, 2239–2245. 
 
Shankar, GM., Bloodgood, BL., Townsend, M., Walsh, DM., Selkoe, DJ., and Sabatini 
BL. (2007). Natural oligomers of the Alzheimer amyloid-beta protein induce reversible 
synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling 
pathway. Journal of Neuroscience 27, 2866-2875. 
 
Shen, K., and Meyer, T. (1999). Dynamic Control of CaMKII Translocation and 
Localization in Hippocampal Neurons by NMDA Receptor Stimulation. Science 284, 
162-167. 
 
Shenoy, SK., Drake, MT., Nelson, CD., Houtz, DA., Xiao, K, Madabushi S., Reiter, E., 
Premont, RT., Lichtarge O, and Lefokowitz RJ. (2006) beta- arrestin-dependent, G 
protein-independent ERK1/2 activation by the beta2 adrenergic receptor. Journal of 
Biological Chemistry 281, 1261–1273. 
 
Shigemoto, R., Kinoshita, A., Wada, E., Nomura, S., Ohishi, H., Takada, M., Flor, P., 
Neki, A., Abe, T., Nakanishi, S., et al. (1997). Differential presynaptic localization of 
metabotropic glutamate receptor subtypes in the rat hippocampus. The Journal of 
neuroscience : the official journal of the Society for Neuroscience 17, 7503-7522. 
 
Shrivastava AN, Kowalewski JM, Renner M, Bousset L, Koulakoff A, Melki R, Giaume 
C, Triller A. (2013) β-amyloid and ATP-induced diffusional trapping of astrocyte and 
neuronal metabotropic glutamate type-5 receptors. Glia. 61, 1673-1686 
 
Skeberdis, VA., Lan, J., Opitz, T., Zheng, X., Bennett, MV., and  Zukin, RS. (2001). 
mGluR1-mediated potentiation of NMDA receptors involves a rise in intracellular 
calcium and activation of protein kinase C. Neuropharmacology  40, 856-865. 
 
 
 
72 
 
Snyder, EM., Nong, Y., Almeida, CG., Paul, S., Moran, T.,  Young-Choi, E., Nairn, AC., 
Salter, MW., Lombroso, PJ., Gouras, GK., and Greengard, P. (2005). Regulation of 
NMDA receptor trafficking by amyloid-β. Nature Neuroscience 8, 1051-1058. 
 
So, CH., Verma, V., O'Dowd, BF., and George SR. (2007). Desensitization of the 
Dopamine D1 and D2 Receptor Hetero-Oligomer Mediated Calcium Signal by Agonist 
Occupancy of Either Receptor. Molecular Pharmacology 72, 450-462. 
 
Soltoff, SP. (1998) Related adhesion focal tyrosine kinase and the epider- mal growth 
factor receptor mediate the stimulation of mitogen- activated protein kinase by the G-
protein-coupled P2Y2 receptor. Journal of Biological Chemistry 273, 23110-23117. 
 
Strack, S., Choi, S., Lovinger, D., and Colbran, R. (1997). Translocation of 
autophosphorylated calcium/calmodulin-dependent protein kinase II to the postsynaptic 
density. The Journal of Biological Chemistry 272, 13467-13470. 
 
Sumi M., Kiuchi K., Ishikawa T., Ishii A., Hagiwara M. (1991). The newly synthesized 
selective Ca2+/calmodulin dependent protein kinase II inhibitor KN-93 reduces 
dopamine contents in PC12h cells. Biochem. Biophys. Res. Commun. 181, 968–975 
 
Thandi, S., Blank, JL., and Challiss, RA. (2002) Group-I metabotropic glutamate 
receptors, mGlu1a and mGlu5a, couple to extracellular signal-regulated kinase (ERK) 
activation via distinct, but overlapping, signalling pathways. Journal of Neurochemistry. 
83, 1139–1153. 
 
Thomas U. (2002). Modulation of synaptic signalling complexes by Homer proteins. J. 
Neurochem. 81, 407–41310.  
 
Tu, J., Xiao, B., Yuan, J., Lanahan, A., Leoffert, K., Li, M., Linden, D., and Worley, P. 
(1998). Homer binds a novel proline-rich motif and links group 1 metabotropic glutamate 
receptors with IP3 receptors. Neuron 21, 717-726. 
 
Tsai, V. W., Scott, H. L., Lewis, R. J., and Dodd, P. R. (2005). The role of group I 
metabotropic glutamate receptors in neuronal excitotoxic- ity in Alzheimer’s disease. 
Neurotox. Res. 7, 125–141 
 
Um JW, Kaufman AC, Kostylev M, Heiss JK, Stagi M, Takahashi H, Kerrisk ME, 
Vortmeyer A, Wisniewski T, Koleske AJ, Gunther EC, Nygaard HB, Strittmatter SM. 
(2013). Metabotropic Glutamate Receptor 5 Is a Coreceptor for Alzheimer Ab Oligomer 
Bound to Cellular Prion Protein. Neuron. 79, 887-902. 
 
Vardy ERLC, Catto AJ, Hooper NM. (2005). Proteolytic mechanisms in amyloid-beta 
metabolism: therapeutic implications for Alzheimer’s disease. Trends Mol Med 11, 464-
472. 
 
 
 
73 
 
Walsh, DM., Klyubin., I, Fadeeva, JV., Cullen, WK., Anwyl, R., Wolf, MS., Rowan, 
MJ., Selkoe, DJ. (2002). Naturally secreted oligomers of amyloid bold beta protein 
potently inhibit hippocampal long-term potentiation in vivo. Nature 416, 535–539. 
 
 
Wang, HY., Lee, DH., Davis, CB., and Shank, RP. (2000). Amyloid peptide Aβ(1-42) 
binds selectively and with picomolar affinity to α7 nicotinic acetylcholine receptors. 
Journal of  Neurochemistry 75, 1155–1161. 
 
Wang, HY., Li, W., Benedetti, NJ., and Lee, DHS. (2003). α7-nicotinic acetylcholine 
receptors mediate β-amyloid peptide-induced tau protein phosphorylation. Journal of  
Biological Chemistry 278, 31547–31553. 
 
Wang, Q., Walsh, DM., Rowan, MJ., Selkoe, DJ., and Anwyl, R. (2004). Block of long-
term potentiation by naturally secreted and synthetic amyloid beta-peptide in 
hippocampal slices is mediated via activation of the kinases c-Jun Nterminal kinase, 
cyclin-dependent kinase 5, and p38 mitogen-activated protein kinase as well as 
metabotropic glutamate receptor type 5. Journal of  Neuroscience 24, 3370-3378. 
 
White, RR., Kwon, YG., Taing, M., Lawrence DS., Edelman, AM. (1998). Definition of 
optimal substrate recognition motifs of Ca2+-calmodulin-dependent protein kinases IV 
and II reveals shared and distinctive features. J Biol Chem. 273, 3166–3179. 
 
Willard, SS., Koochekpour S. (2013). Glutamate, Glutamate Receptors, and Downstream 
Signaling Pathways. Int J Biol Sci. 9, 948-959. 
 
Young K. F., Pasternak S. H., Rylett R. J. (2009). Oligomeric aggregates of amyloid beta 
peptide 1–42 activate ERK/MAPK in SH-SY5Y cells via the alpha7 nicotinic receptor. 
Neurochem. Int. 55, 796–801 
 
Zhang, J.F., Qi, JS., and Qiao, JT. (2009). Protein kinase C mediates amyloid betaprotein 
fragment 31-35-induced suppression of hippocampal late-phase longterm 
potentiation in vivo. Neurobiol. Learn. Mem 91, 226-234. 
 
Zhang, R., and Xie, X. (2012). Tools for GPCR drug discovery. Acta Pharmacology Sin 
33, 372-384. 
 
Zhang, T.,  and Brown, JH. (2004). Role of Ca2+/calmodulin-dependent protein kinase II 
in cardiac hypertrophy and heart failure. Cardiovascular Research 63, 476-486. 
 
Zhao, D., Watson, JB., Xie, CW. (2004). Amyloid beta prevents activation of 
calcium/calmodulin-dependent protein kinase II and AMPA receptor phosphorylation 
during hippocampal long-term potentiation. J Neurophysiol. 92, 2853-2858. 
 
 
 
 
74 
 
Zhou, Y., Takahashi, E., Li, W., Halt, A., Wiltgen, B., Ehninger, D., Li,  G., Hell, JW., 
Kennedy, MB.,  and Silva AJ. (2007). Interactions between the NR2B receptor and 
CaMKII modulate synaptic plasticity and spatial learning. Journal of Neuroscience 27, 
13843-13853. 
 
Zundorf, G., and Reiser, G. (2011). Calcium dysregulation and homeostasis of neural 
calcium in the molecular mechanisms of neurodegenerative diseases provide multiple 
targets for neuroprotection. Antioxidants and Redox Signaling 14, 1275-1288. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
75 
 
NAME:  Fitore Raka 
 
 
POST-SECODNARY EDUCATION 
 
Master of Science                                                                                                              2012-2014 
University of Western Ontario 
Physiology and Pharmacology 
 
Honours Bachelor of  Medical Science                                                                             2008-2012 
University of Western Ontario 
Honors Specialization in Physiology 
 
 
SCHOLARSHIPS 
 
Ontario Graduate Scholarship ($15, 000)                                                                                   2013 
CIHR Strategic Training Program in Vascular Research ($12,000/year)                         2012-2014 
Western Graduate Research Scholarship ($8,000/year)                                                    2012-2014 
Western Admission Scholarship of Distinction ($1, 500)                                                          2008 
 
 
RELATED EXPERIENCE 
 
Teaching Assistant                                                                                                             2012-2014 
University of Western Ontario 
Department of Physiology and Pharmacology 
 
Student Researcher                                                                                                                      2012 
Robarts Research Institute – Dr. Stephen Ferguson 
 
 
POSTER PRESENTATIONS  
 
Role of CaMKIIa in the regulation of Metabotropic Glutamate Receptor 5. Presented at London 
Health Research Day, London ON., 2014. 
 
Regulation of Metabotropic Glutmate Receotir 5 activity by CaMKIIa. Presented at Great Lakes 
GPCR Retreat, Cleveland OH., 2013 
 
 
 
